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ABSTRACT 
Zika virus (ZIKV) outbreaks have been linked to several neurological pathologies in the 
developing fetus, which can progress to spontaneous abortion and microcephaly in 
newborns whose mothers were infected with the virus during pregnancy. ZIKV has also 
been correlated with neurological complications in adults such as Guillain-Barré 
Syndrome (GBS). ZIKV outbreaks often occur in low income areas with limited access to 
healthcare. Therefore, there is a need to create a low-cost preventative vaccine against 
the virus. Mature ZIKV particles contain a lipid bilayer, a positive sense single stranded 
RNA genome and three structural proteins: the envelope (E), membrane (M) and capsid 
(C) proteins. Congruently, to other members of the Flaviviridae family, ZIKV proteins 
are synthesized as a polyprotein precursor which needs to be processed to release the 
mature structural and non-structural viral proteins. Past studies have determined the 
ZIKV precursor protein is cleaved by a host furin protease which separates the Pr peptide 
and the M protein, while the host signal peptidase separates the M and E protein. 
Processing is important for correct folding of the E protein. In turn, the most important 
neutralizing antibodies upon infection are directed against epitopes of the E protein. In 
this work, we used a Bean Yellow Dwarf Viral vector system to transiently express, in 
Nicotiana benthamiana plants, a portion of the ZIKV polyprotein encoding the Pr, M 
and E proteins. I further demonstrate that plants can proteolytically process the 
polyprotein to yield the two integral membrane proteins M and E. These proteins can be 
shown to co-partition into a soluble membrane-particulate fraction, consistent with 
formation of enveloped virus-like particles (VLPs). This work provides the first step in 
creating a low-cost sustainable plant-based production system of ZIKV VLPs that can be 
explored as a potential component 0f a low-cost prophylactic vaccine against ZIKV. 
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1. INTRODUCTION 
Recent outbreaks of Zika Virus (ZIKV) in the Americas revealed the virus as a 
strong cause of malformation in infected human embryos. It is shown to be the source of 
various neurodevelopmental birth defects, including microcephaly as well as 
spontaneous abortions (Hasan et al., 2018). Many of these outbreaks have occurred in 
areas with limited access to medical care and low-capital, capital which would allow 
affected countries to bring treatments, for the virus and virus-associated febrile 
symptoms, in from other areas  (United Nations Development Programme, 2017). 
Though outbreaks of the virus have progressively become less common, RNA viruses, 
like ZIKV, can change their virulence patterns and means of transmission more often 
than DNA viruses. Therefore, ZIKV remains a public-health concern as it could reemerge 
in the future (Monath, 2018). 
Since there is no current FDA approved vaccine against the virus, researchers 
have been working to develop a vaccine against ZIKV should the necessity appear 
(Abbink et al., 2018). While the efficacy and safety of such a vaccine are clearly the major 
objectives, it is imperative such a vaccine candidate be inexpensively and sustainably 
manufactured. This study aims to investigate a possible method to achieve this goal. 
1.1 History of Zika Virus 
ZIKV is a member of the Flaviviridae family and was first isolated in 1947 in the 
Zika Forest of Uganda (Dick, 1952; Dick et al., 1952). The virus did not produce many 
observable side effects for those who contracted it, so it often went ignored and 
undiagnosed (Bearcroft, 1956; Simpson, 1964). In January of 1948, the same group of 
researchers who initially isolated the virus trapped mosquitoes from the same place 
where the virus was originally located. Again, they isolated the virus, but this time from 
the infected mosquitoes, and characterized the previously unrecorded virus as “Zika 
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Virus” (Dick et al., 1952). Years later, manifestations of previously recorded ZIKV 
symptoms appeared in patients who also began to develop jaundice, leading people to 
believe that ZIKV caused jaundice as well. In 1954, William Beacroft found evidence 
supporting that ZIKV was not a contributing factor to jaundice by injecting himself with 
the virus and recording his symptoms. He had no symptoms of jaundice and compared 
his findings to another patient who also did not develop jaundice upon infection with 
ZIKV (Bearcroft, 1956). Intermittent reports of the virus were present in lab workers as 
well as a few laymen through the following years. Many countries, such as Malaysia and 
Indonesia, in the 1970’s and 1980’s began to report scattered virus in mosquitoes, 
animals and rarely in humans  (Garcia et al., 1969; Olson et al., 1981). In 2007 
physicians reported an outbreak of an illness on Yap Island in the Federated Republic of 
Micronesia, characterized by rash, conjunctivitis (inflammation of the conjunctiva 
resulting in “pinkeye”) and arthralgia (joint pain). Serum from these patients contained 
IgM antibodies that cross-reacted against Dengue virus (DENV), although the illness 
seemed clinically distinct from DENV (Duffy et al., 2009; Petersen et al., 2016).  
While only about 50 cases were confirmed, based on the serum presence of anti-
ZIKV antibodies, it is estimated that the Yap-outbreak resulted in 5000 infections within 
a population of only 6700 (Duffy et al., 2009). Retrospective analysis determined that at 
the time cases of microcephaly were also expanding within that population, though no 
record of hospitalization or death was documented from these symptoms (Mlakar et al., 
2016). In 2013 and 2014 there was an outbreak of the same illness in French Polynesia 
where an estimated 32,000 people were assessed for ZIKV infections (Baronti et al., 
2014; Besnard et al., 2014; Cao-Lormeau et al., 2016). In addition, a total of 42 people 
were diagnosed with Guillain-Barré syndrome (GBS), through a study during the 
outbreak and 41 had anti-ZIKV IgM or IgG (Cao-Lormeau et al., 2016; Petersen et al., 
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2016). The incidence for GBS was far higher than previously described for this very rare 
neurological disease. This was the first report for a neurological disorder likely linked to 
infection with ZIKV and was later attributed to  abnormal host-directed immune 
responses resulting from the ZIKV infection (Ritter et al., 2017). 
ZIKV continued its progression eastward across the Pacific Ocean as outbreaks 
were reported in other Pacific Islands including New Caledonia, Easter Island, Cook 
Islands (2014), Samoa (2015) and American Samoa (2016). Sporadic cases continued to 
be reported in South-East Asia as well (Thailand, East Malaysia, Cambodia, the 
Philippians and Indonesia) (Dupont-Rouzeyrol et al., 2015; Roth et al., 2014; Tognarelli 
et al., 2016; Weaver et al., 2016). ZIKV made landfall in South America around the same 
time as these outbreaks, the first non-imported cases were reported in Brazil in June 
2015 (Zanluca et al., 2015). By December of 2015 there were an estimated 1.3 million 
suspected cases worldwide since the beginning of the 2007 Yap outbreak (Faria et al., 
2016; Hennessey et al., 2016).  
While ZIKV local outbreaks were large in respect to the slight population on the 
island nations of the Pacific, its epidemiology gained statistical robustness in Brazil. 
Although most reports continued to be characteristic of mild illness, the large population 
of immunologically naive individuals and the fast spread of the Brazilian ZIKV epidemics 
allowed clinicians to observe an alarming link to what became the most notorious 
pathology associated with ZIKV infection – microcephaly. Microcephaly is a condition 
characteristic of a small head, reduced brain size and impaired cognitive development in 
newborns usually caused defects in neural development (Salvo et al., 2018). Other less 
common fetal abnormalities and spontaneous abortions were also reported as associated 
with ZIKV infections as the epidemic spread from Brazil to other parts of the Americas 
(including the southern US) and the Caribbean Islands (Faria et al., 2016; Schuler-
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Faccini et al., 2016). As of February 2018, a total of 86 countries have reported mosquito 
borne ZIKV transmission (Center For Disease Control, 2018).  
Though fewer cases have been reported in recent days, RNA viruses are subject to 
faster evolution rates than DNA viruses, due to the fact that they lack proofreading 
activity (Elena and Sanjuán, 2005). It is likely that Zika will continue to be involved in 
intermittent cases. Due to past infection patterns and the reputation concerning the 
change in virulence patterns of RNA viruses, it is possible that it could reemerge as an 
epidemic if prophylactic treatments are not created (Monath, 2018). 
1.2 Zika Virus Transmission  
The most common recorded means of transmission of ZIKV is through mosquito 
insect bite. Aedes mosquitoes have been identified as the main genus of transmission, 
primarily Aedes aegypti and Aedes albopictus (Grard et al., 2014). It is thought A. 
aegypti has high vectoral capacity, the capacity for a vector to transmit disease by a 
vector to a host, since its primary feeding source is humans and the species often will bite 
multiple humans in a single meal (Gubler, 2002). Both mosquitoes generally feed during 
the daytime (Ponlawat and Harrington, 2009). This allows them to access the largest 
possible blood supply, as most people are active during the day. Consequently, a large 
number of people have the potential to become infected if bite by an infected mosquito. 
 Transmission through semen has been reported as well (Araujo et al., 2016; Dai 
et al., 2016; Mansuy et al., 2016). Viral particles in addition to viral RNA was detected in 
sperm samples up to 62 days after onset of ZIKV febrile symptoms (Mansuy et al., 2016). 
Studies have also shown detectable ZIKV RNA in vaginal secretions but there have been 
no reports on whether the sexual partner of these patients contracted ZIKV or not. ZIKV 
has also been detected in urine, breast milk, fetal amniotic fluid and saliva of patients 
positive for infection (Paz-Bailey et al., 2017). However, there is little evidence of 
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transmission of the virus through any of these fluids. There is a single report of 
transmission of ZIKV through saliva, in which a ZIKV infected monkey bite a man who 
later developed ZIKV upon medical diagnosis (Leung et al., 2015). As usual with blood-
borne infections, contaminated blood transfusion is also a potential risk that can be 
minimized by screening for ZIKV and avoiding donations from people who recently 
traveled to areas where ZIKV has become endemic (Musso et al., 2014). 
 By far the biggest concern regarding ZIKV infection is its transmission from an 
infected mother to a fetus. There is likely greater vulnerability in the early stages of 
pregnancy since the fetus is developing its neural cells. There is evidence a fetus might 
never develop birth deficiencies by a ZIKV  infected mother if the mother contracts the 
virus during the third trimester of pregnancy (Sotelo et al., 2017). Maternal ZIKV 
infection had also been shown to manifest differently than in subjects who are not 
pregnant, primarily, the mother’s length of symptoms was prolonged in comparison to 
individuals who were not pregnant (Nguyen et al., 2017). There is no evidence that 
previous infection with ZIKV will affect future pregnancies once the virus is cleared from 
a patients system (Rasmussen et al., 2016). 
1.3 Symptoms of Zika Virus Contraction 
 The incubation time of ZIKV is generally anywhere from 3-14 days (Krow-Lucal 
et al., 2017). Most ZIKV infections present asymptomatically, making ZIKV tests 
necessary if a pregnant mother has been bitten by a mosquito in a country where ZIKV 
outbreak is current and prevalent. However, when symptoms are present, they can 
include some or all of the following: fever, sweating, chills, rash, headache, vomiting, and 
conjunctivitis (joint and muscle pain). Other, less frequently-reported symptoms include 
dull hearing, hand and ankle swelling, and subcutaneous bleeding. All previously listed 
symptoms do not last generally more than a week. Though there have been recorded 
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deaths from ZIKV, it extremely unlikely that a patient will die from contraction of ZIKV 
(Petersen et al., 2016).  
Neurological complications in adults after contraction of ZIKV has been reported 
in rare cases, in addition to GBS, paranesthesia as well as muscle weakness that does not 
progress to GBS is on record (Oehler et al., 2014). GBS itself can hinder movement 
sensation or organ function and can eventually lead to flaccid paralysis which is usually 
not permanent. Both the Peripheral Nervous System and the Autonomic Nervous System 
can be affected, and symptoms can progress to final stages in as little as 3-6 weeks post 
infection. Proposed mechanisms for how this might occur include Acute Inflammatory 
Demyelinating Polyneuropathy, which involves activation of the complement system and 
T cells which in turn activate macrophages and damage myelin. Another proposed 
mechanism involves production of IgG antibodies and complement against the 
axolemma (Magira et al., 2003). ZIKV crosses the blood brain barrier (BBB) and infects 
neural progenitor cells (Li et al., 2016). When these cells are infected it is proposed by 
researchers that epitope spreading as well as molecular mimicry can cause the previously 
listed mechanisms to begin (Hadden and Gregson, 2001). Nerves can remyelinate 
themselves within 6-12 months and patients can recover fully (Yuki, 2015).  Other 
extremely rare neurological cases that have been documented in adults in correlation 
with ZIKV are Meningoencephalitis and Acute myelitis; though ZIKV has been 
determined neurotropic, no causative studies have been done on Meningoencephalitis 
and Acute myelitis (Araujo et al., 2016). 
Though the exact mechanism by which ZIKV leads to neurodevelopmental 
pathologies in the embryo or fetus and to microcephaly is not resolute, several possible 
mechanisms have been proposed. According to one proposal, ZIKV triggers endoplasmic 
reticulum (ER) stress and unfolded protein responses as was shown in both ex-vivo 
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cultured neural stem cells (Laguesse et al., 2015) and in-vivo within the cerebral cortex 
of the fetus (Laguesse et al., 2015). The ER stress causes errors in an unfolded protein 
response in cortical progenitors, these progenitors normally allow for development of 
projection neurons (neurons which govern neurogenesis). Therefore,  progenitors 
infected with ZIKV will produce fewer projection neurons and will finally settle in the 
cerebral cortex, leading to apoptosis of those cells, an overall reduction in neurogenesis 
and a consequential smaller than average brain in the ZIKV infected fetus (Gladwyn-Ng 
et al., 2018). 
Reduced growth occurs in many cases as overall size of ZIKV infected fetuses are 
smaller than normal when they are born. Many of these newborns also experience 
hearing loss, vision problems and feeding problems. All these symptoms are due to a lack 
of development in areas of the brain due to neural cell death and can manifest differently 
in each case (Acosta-Reyes et al., 2017; Cugola et al., 2016). Still births have also been 
reported in ZIKV infected pregnant women, though non-ZIKV etiology should not be 
ruled out in these reports since this evidence is still only correlative (Goncé et al., 2018).  
1.4 Molecular Biology of Zika Virus and Protein Makeup 
 Flaviviruses are icosahedral and lipid enveloped. Mature viral Flaviviridae are 
approximately 500 Å and are smaller than immature viral particles which are 
approximately 600 Å in diameter (Hasan et al., 2018). ZIKV contains a single stranded 
positive sense RNA genome that is 10,600 bp long and consists of one long open reading 
frame that encodes a single polyprotein, primarily anchored in the ER by membrane 
spanning transmembrane helices as depicted below in Figure 1.  
 The polyprotein is cleaved by cellular and ZIKV produced proteases while some 
of the products are later glycosylated by glycosyltransferases. There are three main 
structural proteins (the Capsid or C protein, the membrane or M protein [cleaved from 
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the prM protein] and the Envelope or E protein) and seven nonstructural proteins (NS1, 
NS2A, NS2B, NS3, NS4A, NS4B, NS5), each of which contribute to the formation of 
mature ZIKV particles (Davidson, 2009; Hasan et al., 2018). The genome is packaged 
within a lipid bilayer surrounded by approximately 180 copies of both the envelope (E) 
and the membrane (M) glycoproteins. The capsid (C) protein is composed of 100 amino 
acids and takes part in packaging the viral genome as well as formation of the 
nucleocapsid core (Hasan et al., 2018).  
 Glycoproteins prM and E have two transmembrane domains each and are 
approximately 165 and 495 amino acids respectively (Kuhn et al., 2002). It is thought 
the prM protein functions as a chaperone to help folding and assembly of the E protein 
during a cleavage event that occurs post trans-Golgi processing where the Pr is separated 
from the M protein (Lorenz et al., 2002). After this event, the Pr protein is no longer a 
part of the mature virion and only the C, M and E proteins remain. E proteins also 
encompass at least one receptor binding site and a fusion peptide (Hasan et al., 2018).  
9 
 
 
Figure 1: Components of ZIKV Polyprotein (A) Representation of the ZIKV 
gene containing the sequences for the structural and non-structural 
proteins in order (B) Representation of the ZIKV polyprotein embedded in 
the ER membrane. The cleavage sites are identified by arrows whose 
etiology are distinguished by color. 
 
The structures of the ZIKV virion as well as the structure of the C, M and E 
proteins were resolved at high resolution (Kostyuchenko et al., 2016; Sirohi et al., 2016) 
and were found to closely resemble the corresponding structures of DENV. The major 
difference is found in the region that flanks the glycosylation site on the ZIKV E protein 
(Asn 154 in ZIKV and Asn 153 in DENV) where glycosylation occurs. Glycosylation at the 
Asn 154 site in West-Nile Virus, another flavivirus, was linked to neurotropism 
suggesting that it may play a similar role in ZIKV and may be responsible for its 
neurotropism (Beasley et al., 2005).  There exist glycosylation sites (N-,O- and C- linked) 
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in all ZIKV strains. N- linked glycosylation contributes to multiple functions such as 
proteolytic processing, protein trafficking and receptor binding (Vigerust and Shepherd, 
2007). O-linked glycosylation take part in virus/bacteria-host interaction, ligand 
recognition and signal transduction (Steen et al., 1998). C-linked glycosylation is thought 
to play a role in secretion and enzymatic activity (GOTO et al., 2014). N-linked 
glycosylation was found at Asn-154 in the envelope. O-linked glycosylation was found in 
positions (7, 47, 48, 170, 173) of the envelope and positions (6, 8, 56) of the membrane 
protein. C-mannosylation was found only in position 115 of the membrane protein. This 
makes a total of six glycosylation sites in the ZIKV envelope and four in the ZIKV 
membrane protein (Gupta et al., 2016).  
 All Flavivirus precursor proteins also hold seven non-structural (NS) proteins. 
These proteins are NS1, which is involved in replication of RNA as well as assembly of 
the viral particle and when secreted as a hexamer plays a role in immune evasion (Hasan 
et al., 2018; Rastogi et al., 2016), NSA2A, which takes part in immune evasion and RNA 
replication, NS2B, which acts as a cofactor to NS3, NS3, which acts a s major viral 
protease of the polyprotein (as indicated in Figure 1), NS4A, which acts as a cofactor for 
NS3, NS4B which also takes part in immune evasion and RNA replication, and NS5 
which functions in RNA synthesis and modification. All are essential for replication of 
the virus particle (Davidson, 2009; Hasan et al., 2018; Murray et al., 2008).   
 Massive conformational changes occur in virus structure during maturation of 
the viral particle, host-cell recognition and fusion to the host cell. These changes can be 
triggered by both PH and temperature, depending on the developmental stage of the 
particle (Fibriansah et al., 2013). Research on components used for viral replication as 
well as information concerning conformational changes ZIKV undergoes can be valuable 
in development of anti-viral compounds which can be administered post-viral infection. 
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 ZIKV and other flaviviruses enter a host through what is known as receptor 
mediated endocytosis (Hasan et al., 2018). When the virus is inside of the endosome 
irreversible trimerization of the E protein will be triggered by exposure to the acidic 
environment of the organelle. Trimerization results in fusion of viral and endosomal 
membranes (Harrison, 2008). Next, the viral RNA genome is released into the cytoplasm 
of the host cell and the positive sense RNA is immediately translated into the polyprotein 
(Figure 1) which includes both non-structural and structural proteins in an effort to yield 
replication proteins. A double stranded RNA genome is synthesized from the genomic 
strands of single stranded RNA. This allows for transcription and replication of the 
genome, creating new viral mRNAs and ssRNA genomes. Particle assembly occurs at the 
ER, as virions bud and are transported to the Golgi. It is likely that the receptor for ZIKV 
is the Gas6-AXL tyrosine receptor complex. The Gas6 protein can be found mostly in 
brain, muscles and male reproductive tissues while the AXL tyrosine kinase is expressed 
mainly in muscles and male reproductive tissues (Harrison, 2008; Richard et al., 2017). 
Lower amounts of Gas6 and AXL tyrosine kinase have been described in female 
reproductive tissues and importantly in the placenta as well (Uhlén et al., 2015). 
 Immature flavivirus particles form in the ER lumen and are composed of 
uncleaved prM, and E in the lipid membrane and C. It is important to note that these 
particles alone are unable to infect a host cell because they do not contain the RNA 
genome however, any of these structural proteins likely can initiate an immune response 
(Kaufmann et al., 2009). After viral assembly, immature virions transport out of the ER, 
to the trans-Golgi network (TGN), then to the cell surface. During this transit, particles 
undergo protease and pH dependent maturation (Li et al., 2008). The prM protein is 
cleaved by furin proteases (in humans), producing a glycosylated N-terminal pr fragment 
which separates completely from the other proteins while the membrane (M) portion 
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remains anchored to the mature virion. Cleavage and dissociation of the pr peptides 
from a virion primes viral particles once they infect another cell to undergo low-pH 
fusion events during cell entry (Harrison, 2008). Though proteolytic processing of prM 
is essential for viral fusion to host cells, complete maturation of all 60 trimeric spikes is 
not mandatory for infectivity or fusion (Plevka et al., 2011). Though the mature virions 
and immature virions share some similarity there are many differences that allow varied 
functions of each.  
 In a mature flavivirus, the E protein forms a dimer. Each E protein monomer is 
composed of three domains: the first domain is the amino terminal domain (DI), which 
is centrally located in the protein monomer, the dimerization domain (DII) contains the 
fusion peptide and the carboxy-terminal immunoglobulin domain (DIII). A total of 90 E 
protein dimers, composed of a total 180 protein monomers, form the smooth surface of 
the mature flavivirus (Kuhn et al., 2002). The lipid bilayer is mostly unexposed since the 
E dimers are in a close-packed arrangement which is why a conformational change is 
required before fusion with the host cell (Hasan et al., 2018; Kuhn et al., 2002). The 
transmembrane domains from the E and M proteins create antiparallel helices. The two 
helices in the E protein stem region are amphipathic and lie flat on the viral membrane 
to interact with the lipid heads of the outer leaflet of the lipid bilayer. The M protein is 
also helical and an antiparallel coiled-coil (W. Zhang et al., 2003). 
 Immature flavivirus particles are able to be produced upon addition of NH4Cl or 
another base to the growth medium during the final maturation phase because this 
prevents pH driven prM-E rearrangement (Heinz et al., 1994). Immature viral particles 
have only 60 trimeric surface spikes and are larger than mature virions (~600 Å). 
Rearrangement of E and prM proteins occurs in the low-pH environment of the Trans-
Golgi Network (TGN) which drives cleavage of the pr peptide from the prM to generate 
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the mature virus. During this period, the conformation of the immature viral particle 
changes from 60 E trimers to 90 E dimers. In addition, the angle hinge among DI and 
DII in each E protein changes by 27 degrees while the E and M anchor regions are also 
reorganized. The cleaved pr peptide is released as the protein gets secreted to the 
extracellular environment which is typically slightly above neutral pH (Yu et al., 2009). 
The process reverses itself when the virus infects a new host cell. Upon endocytosis, the 
low pH in the endosome causes parallel flat E dimers to disassociate into monomers 
which then re-associate into trimers. These E protein trimers have three-fold symmetry 
and employ class II fusion (a classification of viral fusion proteins that require 
proteolytic processing to create a fusion competent protein, are parallel with respect to 
the viral membrane, utilize beta sheets as their major secondary structure, and have 
dimers as their structure of the native fusion protein) (White et al., 2008). In flaviviruses 
the fusion peptide creates a loop at the end of the E DII. Upon acidification DII inserts 
itself into the host endosomal membrane. When the lipid membranes of the virus and 
the cell fuse, the stem region of E fixes itself to a groove on the side of the DII (Y. Zhang 
et al., 2003). 
1.5 Current Vaccines for ZIKV Infection 
 During the most recent ZIKV outbreaks there were no preventative medical 
treatments available. Spread of disease has been recently prevented by avoidance of 
travel to areas where outbreaks were occurring (Benelli and Mehlhorn, 2016). Recently, 
there have been more specific developments in ZIKV prevention, mainly in the realm of 
vaccine research. 
 Though there is no approved vaccine for ZIKV, there are some currently in phase 
1 clinical trials (Abbink et al., 2018). Most recent attempts at a ZIKV vaccine involve 
DNA vaccines (Tebas et al., 2017), mRNA vaccines (Pardi et al., 2017; Richner et al., 
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2017), Purified Inactivated Virus (PIV) vaccines (Modjarrad et al., 2018) and viral 
vector-based vaccines (Combredet et al., 2003; Lauer et al., 2017; Milligan et al., 2016; 
Ura et al., 2014; ZIKAVAX). Many of these have been shown to display full protection 
against ZIKV challenge in mice and rhesus macaques. There are currently 13 open 
clinical trials testing the previously listed platforms (Abbink et al., 2018).  
 DNA vaccines are composed of a plasmid which contains a promoter as well as a 
transgene under control of that promoter. The first assessment of a ZIKV DNA vaccine 
was done by GeneOne Life Science and Inovio Pharmaceuticals. The DNA vaccine 
expressed both the Zika pre-membrane (prM) and Envelope (E) genes. Mice in this trial 
received a priming dose as well as two boosters. There were no severe reactions to the 
vaccine and it was found to have produced dose-dependent responses when tested 2 
weeks after the last administration in mice (Tebas et al., 2017). Challenge experiments 
were conducted in the interferon receptor knockout mouse model. Serum obtained from 
vaccinated animals was transfused into nave model animals which were then challenged 
by a lethal dose of ZIKV with a 92% survival rate (Aliota et al., 2016).   
Two DNA vaccines were then modeled for human trials. One was designed to 
express the ZIKV prM-E proteins as well as a Japanese Encephalitis Virus (JEV) stem 
region, to increase subviral particle formation. The second was created to produce 
wildtype ZIKV prM-E. In both vaccine trials, volunteers were administered with three 
doses. Both were tolerated well, the vaccine without the JEV stem region had higher 
immunogenicity and is in phase II clinical trials (Abbink et al., 2018; Marques and 
Burke, 2018). 
 There are also three candidate vaccines, all created in different research 
laboratories, based on a purified formalin-inactivated Zika virus (referred to as ZPIV) in 
Phase 1 clinical trials. Upon combined interim analysis, vaccines were shown to elicit 
15 
 
neutralizing antibodies in all participants with a peak after the second dose for 95% of 
participants while the other 5% had peak levels during another unspecified portion of the 
trial. These results also showed protection against ZIKV challenge in 41 of 50 Balb/c 
mice. Another phase 1 trial studying dose escalation is to be started soon (Abbink et al., 
2018). 
 mRNA vaccines encode a gene of interest (Abbink et al., 2018; Brito et al., 2015). 
Once it has entered the cytoplasm, mRNA is translated into protein. The most efficient 
Zika mRNA vaccine contains prM-E mRNA encapsulated by a lipid nanoparticle 
(Reichmuth et al., 2016). The nanoparticle allows for delivery and stability of the mRNA 
(Reichmuth et al., 2016). Immunization using this vaccine in both mice and monkeys has 
induced high levels of neutralizing antibodies against ZIKV (Pardi et al., 2017)When 
pregnant mice were immunized, the vaccines also prevented fetal injury (Richner et al., 
2017). The first phase I/II clinical trial by Moderna Therapeutics is ongoing to determine 
safety and dose-dependent immunogenicity (Pardi et al., 2017; Richner et al., 2017). 
While apparently effective, mRNA vaccines require high dose of the immunogen. 
Moreover, the lability of mRNA makes such vaccines not sufficiently stable at ambient 
temperatures, constituting a major drawback when considering transportation and 
distribution of the vaccine in rural areas of the tropics. 
Vector based vaccines are made up of a viral vector with a genetically engineered 
gene that produces a recombinant protein of interest. A modified schwarz stain of 
measles virus vector vaccine against ZIKV has been developed by Themis Bioscience 
GmbH and is in phase I clinical trials. It was designed to express the ZIKV prM-E and 
was tested for immunogenicity in both mice and in monkeys. The current clinical trial 
aims to assess safety of both high and low doses when given in singular and duplicate 
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administrations; however no results on this trial have been determined yet (Barouch et 
al., 2013). 
1.6 Immune Response to ZIKV 
 There are many cellular receptors that have been proposed as potential entry 
receptors for the virus. ZIKV prefers to attack neuronal cells making the Gas6-AXL 
receptor the most likely candidate (Harrison, 2008). Among other candidates are: 
dendritic cell specific receptors, ICAM-3 grabbing non-integrin, hepatitis A virus cellular 
receptor 1 and tyrosine protein kinase 1 (Hamel et al., 2015; Meertens et al., 2017).  
 Cellular infection with ZIKV encompasses expression of Toll-like 3 receptor 
(TLR3), retinoic acid inducible gene 1 (RIG-1) and melanoma differentiation associated 
gene 5. It also causes the upregulation of type 1 and type 2 interferons as well as the 
upregulation of interferon stimulating gens that mediate antiviral responses (Hamel et 
al., 2015). Though innate immune mechanisms like TLR3 and MDA5 recognize dsRNA 
they recognize ZIKV, a positive sense single stranded RNA virus, because although the 
positive sense strand can be directly translated, ZIKV must create a negative sense RNA 
intermediate before it can make more positive sense strands to be used as genomes for 
future virus particles. As a result, the body recognizes both its primary positive sense 
strand and its negative sense RNA strand as dsRNA and mounts an innate immune 
response to dsRNA rather than ssRNA (Ball, 1994). 
Increase in the expression of TLR3 eventually will cause upregulation of Type 1 
interferon (type 1 IFN) (Uematsu and Akira, 2007). Type 1 IFN can stimulate both NK 
cells and macrophages to elicit an antiviral response. This will cause degradation of RNA 
as well as necroptosis and apoptosis (Madera et al., 2016). Type 1 IFN, when released, 
acts on neighboring cells to increase surveillance.  The Type 1 IFN will be released from 
the cell and will bind to the Type 1 IFN receptor on the neighboring cell which will 
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phosphorylate Signal transducer and activator of transcription 1 and 2 (STAT 1 and 2) 
which signals through IRF9 to upregulate 2'-5'-oligoadenylate synthase (2’5’ OAS) and 
the protein kinase receptor (PKR).  2’5’ OAS uses ATP to become 2'-5'-oligoadenylate 
(2’5’ OA) which causes expression of RNaseL which causes degradation of mRNA and 
halting of transcription as a result. PKR upregulation causes phosphorylation of 
Eukaryotic Initiation Factor 2 alpha (elF2 alpha) which shuts down translation and 
eventually causes apoptosis and necroptosis of the cell (Murphy and Weaver, 2016). 
Upregulation of RIG-1 ultimately causes an upregulation of Type 1 IFN which results in 
the same cell death mechanism previously described, it accomplishes this through 
recognition of the 5' phosphate cap of viral mRNA  (Murphy and Weaver, 2016). 
 Melanoma differentiation associated gene 5 (MDA5) is a RIG-I-like receptor 
dsRNA helicase enzyme that functions as a pattern recognition receptor (PRR) to 
recognize dsRNA greater than 2,000bp. It is also believed that MDA5 recognizes higher 
order RNA structures that form as a product of annealing of complementary RNAs 
generated during a viral infection (Pichlmair et al., 2009). It is considered a DEAD box 
protein as it has a conserved motif Asp-Glu-Ala-Asp (DEAD). Both RIG-1 and MDA5 
contain two N-terminal caspase recruitment and activation domains (CARDs) as well as 
a C-terminal regulatory domain which allow for downstream signaling (Kang et al., 
2002). Both RIG-1 and MDA5 act on IFNβ promoter stimulator 1 (IPS-1). IPS-1 works in 
conjunction with TRAF3 which phosphorylates TBK1 which phosphorylate IRF3/7 and 
causes the release of Type 1 IFN (Kawai et al., 2005). 
 In addition to the previously described effects of Type 1 IFN release, Type 2 
interferon (IFN gamma) is released by activated NK cells and activated T cells. It has 
been shown that ZIKV infected cells have upregulated amounts of IFN gamma (Hamel et 
18 
 
al., 2015).  Such a situation indicates possible activation of NK cells and T cells in 
addition to previously described immune mechanisms (Murphy and Weaver, 2016). 
 Beyond innate immune responses, preliminary reports indicate that neutralizing 
antibodies (usually to E protein) were produced as seen in many other flavivirus 
infections (Dai et al., 2016). There exists significant cross reactivity between ZIKV and 
other flaviviruses, generally to what are believed to be conserved epitopes. This situation 
has made it difficult to determine ZIKV infection by utilization of antibody titer in areas 
where people have previously been infected with other flaviviruses like Dengue. Dengue 
virus (DENV) is the most common mosquito‐transmitted human flavivirus and since 
there is much similarity between DENV and ZIKV, there is also much antigenic overlap. 
This has resulted in antibody-dependent enhancement (ADE), where anti-DENV 
antibodies and antibodies against other flaviviruses increase the infectivity of ZIKV (Paul 
et al., 2016). Several proposed mechanism have been researched to explain why this 
occurs. It is possible the viral surface proteins are fastened with antibodies against a 
virus of one stereotype that binds to a similar virus of a different stereotype, in this case 
an antibody against DENV might bind to ZIKV. The binding is primarily supposed to 
neutralize the virus and keep it from attaching to the cell, instead, the antibody that 
binds to the virus also binds to the Fc- region antibody receptor (FcγR). As a result the 
virus is brought into close juxtaposition and the cell internalizes the virus through a 
normal infection route (Takada and Kawaoka, 2003). 
 In addition, an antibody to a virus meant to neutralize DENV might not 
neutralize ZIKV, instead, the virus is injected into the cell as a virus particle after it is 
sub-neutralized by the antibodies against DENV. When the virus is phagocytosed as an 
antigen-antibody complex, it is then degraded by macrophages. The antibodies no longer 
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sub-neutralize the virus due to acidic conditions of the phagolysosome within the 
macrophage and the virus will become active within that cell (Halstead, 2003).  
 Adaptive immune studies on ZIKV have shown that though antibody-dependent 
enhancement can occur in those previously exposed to other flaviviruses, there is also a 
chance previous exposure can produce neutralizing antibodies against conserved 
epitopes and concerns for ADE occur on a case by case basis (Priyamvada et al., 2017).  
1.7 Biology of Virus Like Particles and Immune Effects 
 Virus like particles (VLPs) are a class of subunit vaccines that mimic the structure 
of an actual virus particle. They are generally recognized by the immune system since 
they present authentic viral epitopes to the immune system (Noad and Roy, 2003). VLPs 
are formed through self-assembly of an envelope or capsid protein of viruses within a 
host cell, generally of mammalian origin for most current VLP vaccines (Grgacic and 
Anderson, 2006). In past studies, patients who were immunized with VLPs were more 
likely to elicit a dominant Th1 immune response (comprised of IgG2a and IgG2b). They 
also were able to elicit a larger panel of antigenically specific neutralizing antibodies 
against viral isolates when compared to subunit vaccines that confined only some of the 
viral epitopes on the actual virus (Bright et al., 2007). The self-assembly of VLPs occurs 
in the same way self-assembly of viruses occurs within a cell. The proteins are generally 
targeted to the area in which the virus normally develops (such as the ER or the plasma 
membrane) and the particles bud to mimic immature virus particle formation (Gheysen 
et al., 1989). Often, these particles will be produced in an expression system, and protein 
analysis will be performed on them to determine that different components are present 
in conformationally correct ways. This protein analysis can be completed by western blot 
analysis and utilization of monoclonal or polyclonal antibody preparations specific to the 
protein of interest (Christensen et al., 1996) 
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 VLPs, like native viral particles, contain relevant epitopes in the proper 
conformation. Such a circumstance is needed to elicit protective antibody responses 
(Zabel et al., 2013). The size of the antigen is also a chief factor in determination of how 
these antigens will gain access to lymphoid organs (Gonzalez et al., 2011). Viral particles 
usually encompass sizes that are between 20 and 200 nm (Zabel et al., 2013). This size 
range allows for drainage to lymph nodes as particles that are less than 200 nm in size 
are brought to subcapsular regions of B cell follicles on the surface of myeloid and B cells 
(Cinamon et al., 2008). VLPs also are generally between 20-200 nm, making their 
transport to lymphoid organs efficient (Zabel et al., 2013). 
VLPs encompass a highly repetitive structure. This will efficiently crosslink a BCR 
upon presentation to it which in turn causes potent B cell activation (Bachmann and 
Zinkernagel, 1997; Zabel et al., 2013). This activation causes B-cell proliferation and 
upregulation of MHC class II and costimulatory molecules. Activation of B cells allows 
for formation of both primary foci and germinal centers (GCs). In primary foci, short 
lived B cell responses are produced, whereas in GCs the B cells can undergo somatic 
hypermutation (in dark zones of GCs) and affinity maturation (in light zones of 
GCs)(Murphy and Weaver, 2016). B cells then travel to boundaries between B-cell and T-
cell areas contained in secondary lymphoid tissues. In doing this, B cells pass through 
the mantle zone where T cells display CD40L which interacts with CD40 on activated B 
cells. Through secretion of cytokines such as IL-4, IL-5, and IL-6, full B cell activation 
can occur, and cells will re-enter the dark zones. These cells will exit as memory B cells 
or long-lived plasma cells with allow for adaptive immune memory responses (long lived 
host immunity to presented antigen)(Murphy and Weaver, 2016; Zabel et al., 2013). The 
repetitiveness of these viral particles and VLPs also facilitates complement fixation 
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which in turn enhances deposition on B cells, further enhancing previously described B 
cell activation and adaptive host immunity (Carter and Fearon, 1992; Zabel et al., 2013).  
 Testing of the immune response to VLPs is like that of most other vaccine 
platforms. Dose dependent immunization should occur to determine the amount needed 
to create a sufficient neutralizing immune response. In addition, dose dependent studies 
should be performed in conjunction with intermittent immunization studies to 
determine if boosters are required for a vaccine platform to create a sufficient immune 
response. Antibody titers in response to the vaccine can be measured by means of an 
enzyme-linked immunosorbent assay (ELISA) both after immunization and after viral 
challenge (Bertolotti-Ciarlet et al., 2003) 
1.8 Components of Bean Yellow Dwarf Virus Expression Vector 
 Geminiviruses, like BeYDV, have DNA genomes able to duplicate in high-copy 
number. This ensues because replication occurs by a rolling circle mechanism that 
functions through a double-stranded intermediate. In addition, this intermediate acts as 
a template for viral open reading frame (ORF) transcription (Mor et al., 2003). Such a 
system allows for speedy production of a particular protein of interest and for this 
reason, was chosen for use in this study. The system used in the proposed expression 
vector utilizes an improved geminiviral vector system that contains three separate 
expressions of protein on a single cassette.  The first segment that expresses a protein 
contains a 35S cauliflower mosaic virus protomer. Regulation of transcription requires 
cis elements like this one in order to express corresponding trans-acting proteins (Benfey 
and Chua, 1990). The 35S promoter is followed by a P19 RNAi suppressor that originates 
from tomato bushy stunt virus.  This 19kDa protein forms dimers that bind to short 
interfering RNAs (siRNA) in an effort to express RNA silencing mechanisms that might 
be used by the plant to inhibit expression of the cassette (Hsieh et al., 2009). Following 
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P19 is protease inhibitor 2 (Pin2) which mediates polyadenylation of the first expression, 
the polyadenylation allows for formation of mature mRNA so that translation can occur 
from it (Diamos and Mason, 2018). 
 The second expression cassette is mostly specific to the expression in this study. 
It contains a Long Intragenic Repeat (LIR) which contains a bidirectional promoter to 
express native genes. These are noncoding regions that contain sequences capable of 
forming a hairpin structure and they contain a conserved 9-base sequence that is found 
in all geminiviruses. LIRs are necessary for initiation of rolling circle replication as well 
as synthesis of the complementary start (Mor et al., 2003). There is also a P35s viral 
promoter is repeated twice. This promoter was taken from cauliflower mosaic virus and 
it increases the frequency of transcription initiation (Mor et al., 2003). Following the 
promoter is the Barley alpha amylase Signal Peptide (BASP) which targets the protein 
immediately followed by the BASP to the ER for correct formation and processing, a 
mechanism most like the actual ZIKV (Mukhopadhyay et al., 2005). Following the BASP 
are DNA sequences that produce the native ZIKV proteins, the pr, M, and E. The Zika pr 
is required during processing of immature viral particles to mature viral particles and 
should be separated from the M protein through cleavage by a furin-like protease. The M 
protein forms the membrane of the particle and it is attached to the envelope of the fully 
formed Zika VLP. Finally, the E protein forms the envelop which generally initiates the 
most immunogenicity upon immune stimulation. The Ext3 allows for the placement of a 
poly A tail at the end of the transcribed DNA strand. Finally, the matrix attachment 
region signals to bind to the nuclear matrix to promote stability post-transcription and 
causes the vector to look more like a segment of chromosomal DNA (Mor et al., 2003). 
This is meant to enhance the expression and transcription of the gene of interest (Phi-
Van et al., 1990).  
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 Finally, the third expression also begins with LIRs which have a bidirectional 
promoter to express native genes. It is followed by C1 and C2. These both encode the rep 
and repA proteins. Thought these are two separate genes they can undergo a splicing 
event which can splice the two genes together. If the splicing does occur, then only the 
rep protein is produced. If no splicing occurs, then repA is produced. The splicing event 
will occur only about half of the time, though both are needed to amplify the DNA. RepA 
conditions the nucleus to be favorable for the replication of DNA. This maintains DNA 
synthesis and allows the cell cycle to remain in S phase because it binds to 
retinoblastoma protein. Rep also has a consensus sequence that allows for binding to 
retinoblastoma protein to make the cell stay in the S phase of the cell cycle. The Short 
intergenic region (SIR) contains a polyadenylation element for the genes before it (Mor 
et al., 2003).  
 Other components of the Gemini vector that are not translated include colE1 ori 
which is the origin of replication for DH5 alpha cells (Eshceria coli). The KanR gene 
allows for the gene to be resistance to kanamycin. TrfA makes a trif protein that will bind 
to the origin of replication for agrobacterium and allow replication to ensure and RK2 
oriv is the origin of replication for agrobacterium (Becker et al., 1992). In conjunction 
with one another, these components of the expression cassette allow for speedy 
production of the protein of interest.  
1.9 Agroinfiltration  
 Agroinfiltration provides a low-cost, scalable, safe and quick means of protein 
production. Such a production platform is preferable for viruses such as ZIKV, where 
many of the countries hit hardest by the virus do not have easy access to healthcare or 
excess currency to spend on medicine to treat the virus and symptoms resulting from it 
(United Nations Development Programme, 2017).  
24 
 
Current leading platforms in biopharmaceutical production are mammalian cells, 
bacteria and yeast, which all carry higher associated production costs in initial laboratory 
tests than those of plants such as N. benthamiana (Evens and Kaitin, 2015). In addition, 
cells such as mammalian cells take more capital to produce in large quantity than plant-
based production methods since plants encompass higher scalability. This scalability is 
achievable since plants produce their protein on a short timescale (only a few days) while 
mammalian cells produce a protein of interest on a much larger timescale (weeks) 
(Fischer et al., 2004). 
In addition, there is supplemental safety associated with plant made 
therapeutics. There exists very low likelihood that plants will carry pathogens harmful to 
humans. Whereas therapeutics made in mammalian cell lines can become contaminated 
with pathogens harmful to humans, making plants a safer alternative platform for 
protein production (Daniell et al., 2009; McCormick et al., 2008) 
Through processes such as vacuum infiltration, large quantities of plants are 
given the ability to transiently express a gene of interest (Chen et al., 2016; Rivera et al., 
2012). Large-scale production is preferred when producing therapeutics that must be 
transported to locations with limited access to medicine and money. 
 Unlike transgene expression, transient expression platforms do not require 
integration of transgenes into the host plant genome. Pre-grown plants, once they have 
undergone agroinfiltration, begin to express the construct of interest in a short time. This 
process can be accomplished in days as opposed to weeks with transgene expression 
allowing for quick access to needed therapeutics (Krenek et al., 2015). Quick access to 
these therapeutics is key in cases where treatment must be created and distributed 
quickly such as outbreaks like the ones witnessed involving ZIKV.  
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Such a method utilizes Agrobacterium tumefaciens. This method was initially 
developed by Kapila et al. in 1997 in which a suspension of recombinant A. tumefaciens 
was infiltrated into tobacco plants (Kapila et al., 1997). The method was successful 
because the A. tumefaciens enables transfer of transfer DNA (T-DNA) to most of the leaf 
cells, allowing them to express transgenes at high levels without a requirement for 
transformation of the entire tobacco plant (Matsuo et al., 2016). The complex 
extrachromosomal T-DNA structures form in the agrobacterium-infiltrated plants 
directly after the leaves are transfected (Yang et al., 2018). The T-DNA normally allows 
for the synthesis of enzymes auxin and cytokinin which enables the plant to 
uncontrollably grow. When used in a biotechnology setting, the opine-synthesis genes 
are removed from the T-DNA and replaced with a gene of interest (Lee and Gelvin, 
2008). Agrobacterium can transfer foreign DNA into both monocotyledons and 
dicotyledonous plants by hijacking host factors and cellular processes then by carrying 
out multiple interactions with host-plant factors (Lacroix and Citovsky, 2013). 
1.10 Study aim 
The aim of this project was to express the Zika prM and E proteins in Nicotiana 
benthamiana plants with the hypothesis that Zika Virus-Like Particles will self-assemble 
within the plant. A Gemini viral expression system was utilized and allowed for quick 
and affordable production of the protein. After verification through western blot 
analysis, the proteins were visualized through Transmission Electron Microscopy to 
ensure particle formation. 
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2. METHODS 
2.1 Construction and Cloning of Expression Vector 
Table 1: 
Primers Used in This Study 
# Name of primer 5’ Sequence 3’ 
1 ZprM-Bsa-F ggGGTCTCTCgTGGTGCCGAGGTCACTAGAC 
2 M13-RHT GGAAACAGCTATGACCATG 
3 35S-F AATCCCACTATCCTTCGC 
4 BASP-G-BSA-R gcGGTCTCCACCAGAAGCAAGAGAAGC 
 
 Initially, construction of the expression vector required procurement of three 
separate vectors. A vector containing the ZIKV prM and E protein (pUC57-ZCME-F) was 
provided by Lydia Meador. A vector containing the barley alpha amylase signal peptide 
or BASP (pBYR2eK2M-BAZE) was provided by Andrew Diamos. A geminiviral replicon 
vector (pBYR2eK2MC-GFP) was provided by Hugh Mason and contained the vector 
backbone for the proposed construct. The final vector was created from these three 
initial vectors. Since one DNA segment from each of these constructs was needed, it was 
imperative to introduce restriction sites shared amongst the segments. PCR was 
performed on template pUC57-ZCME-F with primers ZprMBsaF and M13RHT (Table 1). 
This process created a BsaI site (5’-GAGACC-3’) so BsaI could cut five base pairs 
upstream of the site and create a left sticky end. This process also allowed for creation of 
a Sac I site (5’GAGCTC-3’) on the 3’ end of the amplified segment. PCR was also 
performed on the pBYR2eK2M-BAZE with primers 35s-F and BASP-GB-R (Table 1). 
This process created a Xho I site (5’-CTCGAG-3’) on the 5’ end of the segment and a BsaI 
site (5’-GGTCTC-3’) on the 3’ end of the amplified segment to create a right sticky end, 
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which would be able to anneal with the BASP segment of DNA. This PCR created a final 
segment that was ~240 bp.  
 Next, 30 µL of each PCR was mixed and run on a 1% agarose gel (400 mg 
agarose, 40 ml TAE, 4 µL cybersafe) at 115 V for 50 minutes. The segments were present 
at the predicted positions and were excised and purified using GeneClean© Protocol. A 
total of 8 µL of purified Zika prME PCR segment that originated from pUC57-ZCME-F 
was digested with BsaI-HF and SacI-HF. A total of 8uL of purified BASP PCR segment 
that originated from pBYR2eK2M-BAZE was digested with BsaI-HF XhoI. Finally, the 
pBYR2eK2MC-GFP was digested with SacI-HF and XhoI. The segments were present at 
the predicted positions and were excised and purified using GeneClean© Protocol. 
2.2 Ligation of Segments 
 The purified samples were ligated together by taking 2.83 µL of each purified 
segment (ZprME, BASP, Gemini vector backbone), 1.0µL of 10x ligase buffer and 0.5 µL 
of T4 DNA Ligase. After mixing and spinning down for 2 s at 6000 xg, the ligation was 
allowed to react overnight at 16 °C. Ligation precipitation followed, 0.5 uL of glycogen 
was added to the mix, a 0.5 volume of 7.5 M ammonium acetate. And 1.0 volume (~15.75 
µL) of 2-propanol was added to the mixture. The ligation mixture was put on ice for 10 
minutes and centrifuged at full speed for 5 minutes. Supernatant was decanted and ~450 
µL of 70% ethanol was added and was washed by inversion 4 times. Mixture was spun at 
13,000 RCF. Ethanol was decanted, and tube was placed sideways on a 55 °C heating 
block for 10 minutes. Precipitate was resuspended in 3 µL sterile milli-q water.  
For transformation by electroporation, a 40 µL aliquot of electrocompetent DH5α 
E. coli cells was mixed with 1 µL of resuspended ligation product. The mixture was 
transferred to a dry pre-chilled cuvette and electroporated using an electroporator 
(voltage, capacitance and resistance settings were 2.5 kV, 25 µF, and 200  Ω, 
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respectively). Immediately 0.5 mL YENB  (0.75% Bacto yeast extract, 0.8% Nutrient 
Broth, adjust pH to 7.5 with NaOH) was added and cells were transferred into a 1.5 mL 
tube. They were shaken at 200 rpm for 1 hour then were plated on an LB-agar plate 
supplemented with kanamycin. Ten colonies that grew on this plate were transferred to 
another plate and allowed to grow overnight for screening purposes. Overnight-grown 
colonies were screened to identify transformants by PCR using the primer pairs 35S-F 
and ZM-Spe-R (expected size ~700 bp), and ZE3-Bam-F and Ext3i-R (expected size 
~700 bp). A single positive colony was transferred to YENB media and again incubated 
overnight at 37 °C. Plasmids were extracted from the media the next day and were 
subjected to sequencing to verify successful clones. A. tumefaciens (strain EHA105) was 
transformed by electroporation essentially as described above except that the selective 
growth medium contained kanamycin and rifampicin and was allowed to grow 
overnight. 
2.3 Agroinfiltration and Expression 
A. tumefaciens cells harboring the pBYR2eK2M-ZprME expression vector were 
grown overnight and were harvested by centrifugation for 10 minutes at 5,000 xg. The 
cultures were resuspended in 5 mL of 1x infiltration (10 mM 2-(N-morpholino) 
ethanesulfonic acid (MES), 10 mm MgSO4, pH 5.5). Optical density of the culture was 
read at 600 nm and diluted as needed to OD600 = 0.3 in 1× infiltration buffer using the 
equation C1V1 =C2V2. Culture trials were initially diluted to OD 0.1 in a previous test, but 
plant expression of proteins failed upon Coomassie staining. The resulting bacterial 
suspensions were used to infiltrate 6-week-old N. benthamiana plants. Infiltration was 
accomplished by injecting the bacterial suspension into the leaves using a needle-less 
syringe after making a small puncture in the leaf (Huang et al., 2009). After infiltration 
was complete, plants were stored in a 25 °C growth chamber for four days until harvest.  
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2.4 Small Scale Extraction of Proteins 
Agroinfiltrated-leaf tissue samples were homogenized with an approximately a 
1:4 ratio (weight in mg: volume in µL) of extraction buffer. Extraction buffer for the first 
sample of leaf tissue was PBS (0.0100 M Na2HPO4, 0.0018 M KH2PO4, 0.1370 NaCl and 
0.0027 KCL pH=7.4) with 0.1 M sodium ascorbate, 1 mM phenylmethylsulfonyl fluoride 
(PMSF). Where indicated Triton X-100 was added to the specified concentrations.  
Approximately 4 samples of 200 mg of infiltrated leaf tissue were placed in their 
respective 1.7 ml microcentrifuge tube and appropriate amounts of ice cold extraction 
buffer were added. Half (2) of the samples included tubes that contained infiltrated leaf 
tissue extracted in the first buffer listed and the other half (2) contained infiltrated leaf 
tissue extracted in the second buffer listed, which contained Triton-X 100. The same 
process listed proceeded for 4 un-infiltrated leaf tissue samples to act as a control to 
compare to the infiltrated leaf tissue samples. Four metal beads were added to each tube 
and the tubes were placed a bead beater (Next Advanced Bullet Blender 24) for 5 rounds 
of 2 minutes each. Tubes were placed on ice in between each 2-minute round for 30 
seconds. Crude extract was centrifuged at 10,000 xg for 10 minutes at room 
temperature.  Supernatant was then separated from the pellet and the pellet was stored 
at -80 °C separately.  
2.5 Protein Purification Steps for Small Scale Extraction 
 Since samples were performed in duplicate, one sample of each preparation 
(Infiltrated w/ extraction buffer, Infiltrated w/ extraction buffer +1% triton, un-
infiltrated w/ extraction buffer, un-infiltrated w/ extraction buffer + 1% triton) was 
purified by acid preparation to test protein stability. A total of 500 µL of each duplicated 
sample’s supernatant was taken and 16 µL of phosphoric acid was added. The tubes were 
placed in a 4 °C cold room for 10 minutes on a rotator. Then the samples were taken and 
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18 µL of NaOH was added to each tube to bring the samples back to equilibrium. 
Samples were again spun down at 10,000 xg for 10 minutes and supernatant was taken 
and transferred to a new 1.7 ml microcentrifuge tube to be used for SDS-PAGE and 
western blot analysis.  
2.6 SDS- PAGE and Immunoblotting  
 For SDS-PAGE, plant proteins were mixed with 5×.non-reducing sample buffer 
(3.0 ml glycerol, 1g Sodium Dodecyl Sulfate, 7 ml 4xtris (pH 6.8) at 0.5 M, 1.2 ml 
bromophenol blue, 2 ml ddH2o). The samples were separated on 10% polyacrylamide 
gels (5 ml of 40% Acrylamide/Bis Solution [AA/BA] 37.5:1, 2.5 ml 3 M Tris PH 8.8, 12.5 
ml ddH2O, 1:1000 ammonium persulfate [APS] and 1:10000 N,N,N,N, Tetramethyl-
ethylendiamine [TEMED]) at 100 V for 1.5 hours. Gels were then transferred onto 
polyvinylidene difluoride (PVDF) membrane in ice cold PVDF transfer buffer (100 ml of 
10 X transfer buffer [144 g glycine, 30 g tris base= 384 mM Glycine and 50 mM Tris PH 
to 8.3], 200 mL methanol and 700 ml ddH2O) at 110 V for 18 minutes. PBST (PBS with 
0.002% Tween-20) was mixed with a 5:100 (w:v) evaporated milk to create 5% PBSTM. 
PVDF membranes were blocked in 5 % PBSTM overnight. The next day they were 
washed with PBST for 5 rounds of 5 minutes each.  
 Both monoclonal and polyclonal antibody probes were used in this study, post-
SDS-PAGE to determine which proteins were present in samples. Monoclonal antibodies 
detect only a specific epitope on an antigen. As a result, all antibodies applied to the 
transfer membrane should target the same epitope. The monoclonal antibody used in 
this study conformationally recognizes the ZIKV envelope domain II-III fusion loop and 
was provided by Mary Pardhe and Hugh Mason. It only recognizes this epitope if the 
protein is in the correct shape. As a result, only non-reducing samples will yield positive 
results when this antibody is utilized. The use of such an antibody ensured the protein 
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being produced was like the native ZIKV protein and would be likely to initiate an 
immune response to the actual ZIKV if the patient was exposed to it in the future.  
 Polyclonal antibodies recognize multiple epitopes on a single peptide. Since these 
antibodies are produced in animals who also have adaptive immune responses to other 
peptides, cross reactivity to antigens that the polyclonal antibody preparation might not 
have been intended for may occur (Hanly et al., 1995). 
After being washed with PBST, membranes were incubated in a 5 ml solution 
containing 1% PBSTM and a 1/50 dilution of the monoclonal antibody targeting the Zika 
E protein domain II-III fusion loop. Membranes were incubated at room temperature 
(RT) for 2 hours. They were then washed again in PBST for 5 rounds of 5 minutes each 
and were incubated in a solution containing 1% PBSTM and a 1/5,000 dilution of a 
secondary goat anti-human HRP linked antibody at RT for 2 hours. The membranes 
were washed in PBST again for 5 rounds of 5 minutes and were exposed to developing 
solution (Western Blotting Luminol Reagent 750 µL of Solution A and 750 µL of Solution 
B, Santa Cruz biotechnology) and were developed to determine protein presence. 
2.7 Time Course to Determine day of Highest E Protein Expression 
 A new set of N. benthamiana plants was infiltrated, at 2 days post infiltration 
(DPI) two leaves were taken as samples. Approximately 200 mg of leaf material was 
taken from the leaves and frozen. This process was repeated for 3, 4, and 5 DPI. Each of 
the samples were extracted in PBS as described in the small-scale extraction section and 
aliquots of the soluble fraction were set aside for both reduced and non-reduced samples. 
After creation of the samples they were run on 10% polyacrylamide gels, were transferred 
onto PVDF membranes and were incubated using both the monoclonal anti-Zika E 
antibody and the polyclonal anti-Zika E antibody. After obtaining developments the 
32 
 
images were scanned using ImageJ software and the intensity of the bands present in the 
~54 kDa range were determined. 
2.8 Determination of Protein Solubility 
 To ensure the detected ZIKV E protein was present in the supernatant rather 
than the pellet, further solubility determination tests were done following the schematic 
displayed in Figure 2 below. Small scale extraction took place for a single construct 
infiltrated leaf tissue sample utilizing PBS extraction buffer. After the extraction was 
complete the supernatant was set aside, and the pellet was again resuspended in 800 µL 
of PBS extraction buffer, four metal beads were placed into the sample and it was placed 
back into the bead beater for 5 rounds of 2 minutes each, sample was placed on ice for 30 
seconds in between each 2-minute round. The sample was centrifuged at 10,000 xg for 
10 minutes and the supernatant was separated from the remaining pellet. This process 
was repeated using the pellet that resulted from the previous extraction. The pellet was 
mixed with 800 µL of PBS Extraction buffer that contained 0.1% Triton- X 100. Four 
metal beads were placed into the sample and it was placed back into the bead beater for 5 
rounds of 2 minutes each. The sample was centrifuged at 10,000 xg for 10 minutes and 
the supernatant was separated from the remaining pellet. This process was again 
repeated using the pellet that resulted from the previous extraction. The pellet was then 
mixed with 800 µL of PBS extraction buffer that contained 1% Triton-X 100. The 
supernatant was separated from the pellet, was mixed with non-reducing sample buffer 
and all samples were ran on a 10% polyacrylamide gel at 100 V for 1.5 hours, transferred 
to PVDF membranes and probed with the monoclonal anti-Zika E domain II-III fusion 
loop antibody used previously. The membranes were then developed using methods 
previously described.  
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At a later date, the same extraction protocol was followed on a different set of leaf 
tissue samples that harvested the same way as all samples used in this study and was 
extracted in PBS. The supernatant samples were then also mixed with reducing sample 
buffer and were boiled for 5 minutes or were mixed with non-reducing sample buffer. 
These samples were run on a 10% polyacrylamide gel, transferred to PVDF membranes 
and probed with either polyclonal anti-Zika E, polyclonal anti-Zika prM or polyclonal 
anti-Zika M. The first sample set aside in Figure 2 (Supernatant transferred to a new 
tube after extraction of the pellet in PBS) was not ran on these gels due to lack of space 
available on the gel.  
 
Figure 2: Schematic Displaying the Sequence of Extractions to Determine 
Protein Solubility in the Sample. 
 
2.9 Large Scale Protein Extraction 
The agroinfiltrated leaf tissues harvested at 4 DPI (20 g), samples were 
homogenized with an approximately 1:2 ratio (weight in g: volume in ml) of extraction 
buffer. Extraction buffer for all samples of leaf tissue was PBS extraction buffer. Leaf 
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tissue and ice-cold extraction buffer were homogenized with the appropriate volume of 
extraction buffer using a Bullet Blender machine (Next Advance, Averill Park, NY). The 
homogenized leaf tissue was then placed in a beaker, covered in parafilm and rotated for 
30 minutes with a 1.5-inch-long stir bar at 4 °C. The homogenate was centrifuged at 
10,000 xg for 10 minutes at 4 °C. The supernatant was separated from the pellet and the 
pellet was stored at -80 °C for further use.  
2.10 Sucrose Gradient 
 Primarily, a 10% sucrose gradient (5 g sucrose in 50 mL PBS), a 20% sucrose 
gradient (10 g sucrose in 50 mL PBS), a 30% sucrose gradient (15 g sucrose in 50 mL 
PBS), a 40% sucrose gradient (20g sucrose in 50 mL PBS) and a 50% sucrose gradient 
were created. As seen in Figure 3A, the first gradient that was ran contained 2 ml of 50% 
sucrose gradient at the bottom of a 15 mL centrifuge tube, 2 ml of 40% sucrose gradient 
above that layer, followed by 2 ml of 30% sucrose gradient, 2 ml of 20% sucrose gradient, 
2 ml of 10% sucrose and 4 ml of supernatant isolated from the homogenate (Fig 3A).  
 The second sucrose gradient prepared utilized a 20% sucrose gradient and a 70% 
sucrose gradient. The bottom of the tube contained 2 ml of 70% sucrose, 2 mL of 20% 
sucrose above that layer and 8 ml of supernatant from the extracted leaves (Fig 3B). 
Sucrose gradients were centrifuged in an ultracentrifuge with a 28,000 rotor at 28,000 
rpm for 2.5 hours. Extracts were carefully taken out of the tubes with a flat tip pipette to 
ensure accuracy of results when examined by western blot analysis. 
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Figure 3: Schematics of Gradient Setup (A) A sucrose gradient containing 
10%, 20%, 30%, 40% and 50% sucrose was made to isolate particle (B) A 
sucrose gradient containing 20% and 70% sucrose fractions meant to 
condense the VLPs at an “interface band.” (C) An OptiPrep gradient 
containing 10%, 40%, and 60% gradients meant to condense the VLPs at an 
“interface band” from viewing under TEM.  
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2.11 Determination of Protein Components Utilizing Different Ab Probes 
 Samples taken from the sucrose gradients in Figure 3A and Figure 3B were 
initially mixed with non-reducing sample buffer and ran on a 10% polyacrylamide gel at 
100 V for 1.5 hrs. Gels were then transferred onto PVDF membrane in ice cold PVDF 
transfer buffer (100 ml [384 mM Glycine and 50 mM Tris PH=8.3], 200 mL methanol 
and 700 ml ddH2O) at 110 V for 18 minutes. PVDF membranes were blocked in 5% 
PBSTM solution overnight. The next day they were washed with PBST for 5 rounds of 5 
minutes each. Membranes were then incubated in a 5 ml solution containing 1% PBSTM 
and a 1/1000 dilution of the same monoclonal antibody targeting the Zika E protein 
domain II-III fusion loop that was used in previous tests, but this aliquot of the antibody 
was from a different prep than those previously used in the study. The membranes were 
incubated at RT for 2 hours. The membranes were then washed again in PBST for 5 
rounds of 5 minutes each and were then incubated in a solution containing 1% PBSTM 
and a 1/5,000 dilution of secondary goat anti-human HRP linked antibodies at RT for 2 
hours. Membrane was again washed with PBST five times for five minutes each, was 
doused in developing solution (Western Blotting Luminol Reagent 750 µL of Solution A 
and 750 µL of Solution B, Santa Cruz biotechnology) was developed to view presence of 
proteins.  
 Next, 200 µL aliquots were taken in duplicate from sucrose gradients in Figure 
3B after centrifugation. One of the respective samples was mixed with 5x non-reducing 
sample buffer while the other was mixed with 6x reducing (3.0 ml glycerol, 0.93 g DTT, 1 
g SDS, 7 ml 4x tris (pH 6.8) 0.5 M, 1.2 mg bromophenol blue) sample buffer. All samples 
were ran on a 10% polyacrylamide gel. The sample gel with the same samples and 
conditions was ran in triplicate for both reducing and non-reducing samples. Gels were 
then transferred onto PVDF membrane in ice cold PVDF transfer buffer at 110 V for 18 
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minutes. PVDF membranes were blocked in 5% PBSTM solution overnight. Then washed 
with 1x PBST for 5 rounds of 5 minutes each. Membranes were each incubated 
differently. Membranes containing non-reduced samples were incubated in a 5 ml 
solution containing 1% PBSTM with either a polyclonal anti-Zika E antibody, a 
polyclonal anti-Zika prM antibody or a polyclonal anti-Zika M antibody at 1:5000, 
1:5000, and 1:3000 dilutions respectively (3 separate non-reducing incubations total). 
Next, membranes containing reduced samples were incubated in a 5 ml solution 
containing 1% PBSTM with either a polyclonal anti-Zika E antibody, a polyclonal anti-
Zika prM antibody or a polyclonal anti-Zika M antibody at 1:5000, 1:5000, and 1:3000 
dilutions respectively (3 separate reducing incubations total). The membranes were 
incubated at RT for 2 hours then washed again in PBST for 5 rounds of 5 minutes each. 
They were then incubated in a solution containing 1% PBSTM and a 1/5,000 dilution of 
secondary goat anti-rabbit antibodies at RT for 2 hours. The membranes were again 
washed with PBST five times for five minutes each, were doused in developing solution 
(Western Blotting Luminol Reagent 750 µL of Solution A and 750 µL of Solution B, Santa 
Cruz biotechnology) and were developed. 
2.12 OptiPrep Gradient Preparation  
 To visualize the sample, Transmission Electron Microscopy image (TEM) of the 
VLPs was to be performed, An OptiPrep gradient was set up as shown in Figure 3C. 
Initially a PEG precipitation took place. In this experiment, a normal large-scale 
extraction took place except after the supernatant was obtained, 8% polyethylene glycol 
(PEG) 6000 (Chem Cruz) was added to the supernatant and the supernatant/PEG 
mixture was spun on ice, after ~2 hrs samples about 20 ml was taken from solution and 
set aside in -80 °C. The remainder of the sample was allowed to spin on ice overnight-
(~10 hrs). The next morning the mixture was spun down at 16,000 g for 20 minutes at 4 
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°C and the supernatant was separated from the pellet. The pellet was saved and was 
resuspended in half the original volume of the sample in PBS, creating a 2X protein 
concentration. The OptiPrep gradients are twice as dense as sucrose gradient but can 
semi-purify a protein and allow one to view the image under electron microscopy. To 
separate the plant protein from the Virus-like particles, an OptiPrep gradient which 
contained 2 ml of 60% OptiPrep gradient at the bottom of the tube, 2 ml of 40% 
OptiPrep gradient above that layer, 10 ml of 10% OptiPrep gradient above that layer and 
finally 4 ml of the samples taken after 2 hrs was placed on top (as seen in Figure 3C). 
Another tube contained the same setup except that instead, the 2x concentrated PEG 
precipitation were put at the top of the OptiPrep. The gradients were   run at 28,000 rpm 
for 2.5 hours and samples were taken. The interface bands between the 10% and 40% 
fractions were saved and used for TEM. 
2.13 Transmission Electron Microscopy 
 The semi-purified extract of the interface band from the tube that contained the 
samples taken after 2 hrs was fixed to a TEM mesh and was negatively stained with 1% 
uranyl acetate. After 5 minutes, the excess stain was removed from the mesh and the 
mesh was washed twice with ddH2O. The sample was patted with a chem wipe to remove 
excess water. The mesh was then allowed to dry for 15 minutes before it was imaged with 
a CM12 transmission electron microscope.  
3. Results 
3.1 Plasmid Construction and Colony Screening 
The PCR from the pUC57-ZCME-F vector of the Zika prME gene block yielded 
the expected size when ran on a 1% agarose gel (~2.2 kb). The PCR from the 
pBYR2eK2M-BAZE vector of the BASP gene block also yielded the expected size when 
ran on 1% agarose gel (~240 bp). After restriction digestion, all segments again yielded 
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the expected sizes on 1% agarose gels: Zika prME: ~2 kb, BASP: ~150 bp, Gemini 
Backbone: ~12 kb.  After purification of these segments was performed and ligation 
occurred, cells were electroporated and plated. As previously stated, colonies were taken 
from this plate for a colony screen. All 10 colony screens of cells electroporated with the 
results of the ligation precipitation displayed growth on kanamycin plates. When 
subjected to PCR screening with primers 35S-F and SM-Spe-R the correct size was 
observed for all 10 samples (~700bp). Plasmid preparations were completed for the first 
2 samples ran on the gel. When submitted for sequencing the plasmid was found to be 
correct with no mutations. Agrobacterium strain EHA105 was transformed with the 
plasmid and a culture was grown over night. Figure 4 below displays the vector in 
addition to the insert containing the code for the proteins of interest that are displayed  
in Figure 5.  
 
Figure 4: Final pBYR2eK2M-ZprME Expression Vector: This vector 
depiction is displaying the detailed insert that codes for protein of interest 
(as previously described in Introduction section 1.8). 
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Figure 5: pBYR2eK2M-ZprME Expression Cassette and Sizes of Functional 
Proteins that Can be Produced.  
 
3.2. Verification of Conformational Zika E Protein Expression in N. benthamiana by 
Western Blot Analysis.  
 To determine if there was expression of the Zika E protein post-infiltration, leaf 
tissue from construct-infiltrated N. benthamiana plants was harvested 4 DPI. In 
addition, samples from un-infiltrated plants (UN) were also harvested at 4 DPI. Proteins 
in crude extracts from harvested leaves were resolved by SDS-PAGE and subjected to 
immunoblotting (Fig. 6A). When probed with a monoclonal antibody (mAb) against the 
ZIKV E protein domain II-III fusion loop, a major protein band of ~54 kDa was 
demonstrated (Fig. 6A) in all samples from infiltrated leaves, whether they were 
extracted with or without Triton X-100 (1%). In contrast, UN leaf tissue samples 
extracted in either condition did not contain a protein that reacted with the anti-E-
41 
 
fusion-loop mAb. It is therefore likely that the E protein (expected MW of 54) 
accumulates in leaves following transient expression with our construct (Fig. 6A).  
  It was determined whether the produced 54 kDa protein was acid stable, in an 
effort to optimize future purification conditions. Additional leaf material from the same 
infiltrated plants was extracted and purified using the acid preparation purification 
procedure described in the methods section 2.5. In acid prepared UN leaf tissue 
extracted in PBS or PBS that contained Triton X-100 (1%), there was no signal detected 
by western blot analysis. Acid prepared infiltrated samples extracted in PBS and a 
mixture containing both PBS and Triton X-100 detergent both showed signal when 
probed with the anti-Zika E monoclonal antibody. Both samples showed a signal around 
~54 kDa, the expected size of the fully formed Zika E protein (Fig 6B).  
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Figure 6: Verification of Zika E Protein Expression in N. benthamiana by 
Western Blot Analysis. (A) Western blot of Uninfiltrated supernatant (UN 
sup) extracted in PBS, UN sup extracted in PBS and 1% triton, supernatant 
from samples infiltrated with construct-infected  A. tumefaciens (I sup) 
extracted in PBS, and I sup extracted in PBS and 1% triton. All samples were 
probed with an anti-Zika E monoclonal that targeted the Zika E protein 
domain II-III fusion loop. (B) Western blot of uninfiltrated supernatant (UN 
sup) extracted in PBS and purified by acid preparation (acid), UN sup 
extracted in PBS and 1% triton (acid), supernatant from samples infiltrated 
with construct-infected  A. tumefaciens (I sup) extracted in PBS (acid), and I 
sup extracted in PBS and 1% triton (acid). All samples were probed with an 
anti-Zika E monoclonal that targeted the Zika E domain II-III fusion loop. 
 
3.3 Time Course to Determine peak Zika E Protein Expression 
 A time course was completed to determine which day was optimal for taking leaf 
tissue in future studies, based on the degree of ZIKV E protein present. Construct 
infected leaf material that was run under non-reducing conditions consistently yielded 
recognizable bands around the 54 kDa range, the size of the ZIKV E protein, while 
samples under reduced conditions did not reveal prominent bands in the ~54kDa range 
when the same samples were probed with both the conformational monoclonal anti-Zika 
E antibody (Fig. 7A) and when probed with the polyclonal anti-Zika E antibody (non-
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conformational) (Fig. 7B). Under non-reducing conditions the conformational antibody 
displayed the most intense bands at 3 and 4 DPI. With the lowest intensity at 5 DPI. 
Upon quantitative analysis, it was determined that 3 and 4 DPI contained similar 
intensity of bands (Fig. 7C). When samples were under reducing conditions and probed 
with the same monoclonal antibody previously described, the most intensity was seen at 
2 DPI and the intensity of the bands decreased each sequential day (Fig. 7A and 7C). 
 Far more degradation product was detected by the polyclonal antibody probe 
than in the monoclonal antibody probe. However, the intensity of these bands was not 
tested since the main interest is in the presence of the fully formed Zika E protein. The 
intensity under nonreducing conditions was found highest in Day 5 samples when 
probed with anti-Zika E polyclonal antibodies (Fig. 7B and 7C). When these samples 
were run under reducing conditions and probed with the polyclonal anti-Zika E 
antibody, signal was not detectable on the western blot (Fig. 7B) and the intensities were 
almost non-existent (Fig. 7C) and could be attributed to background.  
 It should be noted that these interpretations are not exact and although they are 
quantitative, only provide rough estimates.  
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Figure 7: Time Course to Determine Day of Highest ZIKV E Protein 
Expression: (A) Western blot of leaf tissue samples picked on 2, 3, 4, 5 DPI 
ran under both reducing and non-reducing conditions and probed with 
conformational monoclonal anti-Zika E. (B) Western blot of leaf tissue 
samples picked on 2, 3, 4, 5 DPI ran under both reducing and non-reducing 
conditions and probed with polyclonal anti-Zika E. (C) Kinetic analysis of 
the westerns in (A) and (B) to quantitatively determine the approximate 
intensity of each band. 
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3.4 Determination of Protein Solubility 
 It was imperative to determine if all the previously detected Zika E protein was in 
the soluble fraction or insoluble fraction of the homogenate. At this point in the study 
antibodies were also acquired that detected Zika prM and M proteins. To this end, we 
have used differential centrifugation following various treatments as outlined in Figure 
3. The supernatant samples from all stages of the experiment and the resuspended final 
pellet were resolved by SDS-PAGE and subjected to immunoblotting using the anti-E-
fusion-loop mAb as a probe (Fig. 8A). Importantly, all the E protein that accumulates in 
plants that also can react with the mAb can be found in the aqueous fraction (first 
supernatant, Fig. 8A lane 1). Additional reactive E-protein cannot be extracted from the 
water-insoluble pellet by increasing concentrations of the neutral detergent Triton X-100 
(Fig. 8A, lanes 2-4) nor can we detect additional reactive E protein in the remaining 
pellet (Fig. 8A lane 5).  Since the anti-E-fusion-loop mAb cannot detect the E protein if it 
is denatured, the samples were never run under reducing conditions then probed with 
this antibody. 
 When samples were probed under non-reducing conditions and probed with 
polyclonal anti-Zika prM, there was signal detected in the soluble fraction that was 
removed directly after centrifugation mainly slightly above 37 kDa and slightly around 
50 kDa. There was also slight detection in the soluble fraction obtained after 
centrifugation of the pellet in 1% Triton X-100 + PBS (Fig. 8B). There was no signal 
detected in the pellet for this trial. In addition, all samples that were ran under reducing 
conditions did not display significant signal (Fig. 8B).  
 When the samples were probed with a polyclonal anti-Zika E antibody under 
non-reducing conditions, there was again signal detected in the soluble fraction that was 
removed directly after centrifugation. This signal was slightly above 37 kDa and slightly 
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below 50 kDa. There was also slight detection in the soluble fraction obtained after 
centrifugation of the pellet that was resuspended in 0.1% Triton X-100 + PBS and 1% 
Triton X-100 + PBS, this signal was also slightly above 37 kDa and slightly below 50 kDa. 
The pellet under non-reducing conditions did not display any signal (Fig. 8C). When ran 
under reducing conditions and probed with the polyclonal anti-Zika E antibody, the only 
significant signal was seen in the pellet. This band was also higher than the other bands 
detected on the same gel at slightly above 50 kDa (Fig. 8C).  
 When these same samples were running under both reducing and non-reducing 
conditions and probed with a polyclonal anti-Zika M antibody, there was signal in almost 
every lane at a band estimated to be around 30 kDa. It was determined later in the study 
that these bands were a reaction to plant protein as supported in Figure 10D. Excluding 
the bands that displayed signal because of cross-reactivity to plant protein, the only 
significant band that displayed signal was seen in the soluble fraction of the pellet that 
was resuspended in PBS + 1% Triton (Fig. 8D). This band was slightly above the 50 kDa. 
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Figure 8: Western Blots with Samples that Each Were Extracted by 
Increasingly Stressful Means (A) Samples probed with monoclonal anti-Zika 
E antibody ran under non-reducing conditions only. (B) Samples probed 
with polyclonal anti-prM under both reducing and non-reducing conditions. 
(C) Samples probed with polyclonal anti-E under both reducing and non-
reducing conditions (D) Samples probed with polyclonal anti-Zika M under 
both reducing and non-reducing conditions. 
 
3.5 Western Blot Analysis of Sucrose Gradient to Determine VLP Formation.  
 There have not previously been studies where Zika VLPs express the Zika pr, M 
or E proteins in plants. Under these circumstances, methods detailing isolation of the 
A B 
 
C 
 
D 
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supposedly formed particle have also not previously been completed. To isolate the 
particle a series of sucrose gradients were performed. Primarily, supernatant from 
infiltrated plant extract was run on a sucrose gradient that contained 10%, 20%, 30%, 
40% and 50% sucrose. When probed with a Zika anti-E conformational monoclonal 
antibody, which targeted the Zika E protein domain II-III fusion loop, signal at ~54 kDa 
was seen in all samples except for the 40% fraction. In addition, there was a band seen 
slightly above 150 kDa that was also detected in all gradient samples tested. Signals were 
strongest in the supernatant and the 10% fraction, in which both a ~54 kDa and a ~38 
kDa degradation product were detected (Yang et al., 2018). However, the ~38 kDa 
degradation product began to disappear as the gradients became denser in the 20%, 30% 
and 40% fractions (Fig. 9). 
 
Figure 9: Western Blot Analysis of a Sucrose Gradient to Determine Rate at 
Which Identified Recombinant Zika E Protein Travels. The supernatant 
(sup), 10% fraction (10%), 20% fraction (20%), 30% fraction (30%), 40% 
fraction (40%) and 50% fraction (50%) were ran on the gel above after 
running the sucrose gradient cycling at 28,000 rpm for 2.5 hours. 
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3.6 Western Blot Analysis of Concentrated Sucrose Gradient Samples Using Different 
Ab Probes.  
 Extractions from construct infiltrated leaf tissue were ran on a 20%:70% sucrose 
gradient to create a concentrated interface band, as previously described in the methods 
section and seen in Figure 3B. When a sample of the interface band was taken from the 
same extraction and sucrose gradient run and probed with different polyclonal 
antibodies, a signal was seen in all probes at ~75 kDa (Fig 10. A-C), the expected size of 
the full uncleaved Zika prME expression cassette. When probed with a polyclonal 
antibody targeting the Zika E protein, there was a signal detected at ~54 kDa, the 
expected size of the fully formed Zika E protein (Fig. 4, Fig. 10 A Lane 6). There was no 
signal detected at ~54 kDa when the samples were probed with polyclonal antibodies 
that targeted the Zika prM protein or polyclonal antibodies that targeted the Zika M 
protein (Fig. 10 B and C).  
 Finally, there was no signal below the 15 kDa marker when the interface sample 
was probed with the polyclonal anti-Zika E. However; there was a signal band detected 
below the 15 kDa marker in both samples probed with either the polyclonal anti-Zika 
prM or the polyclonal anti-Zika M. The expected size of Zika prM and Zika M proteins 
when expressed are ~10 kDa and ~8.5 kDa respectively. When probed with anti-prM, 
there were multiple segments detected in the 0% sucrose, 20% sucrose and interface 
sections of the gradient that were below 15 kDa.  In addition, it was also noted that there 
was a small band present just above the 25 kDa range in a lane of sucrose gradient 
samples in the 20% fraction, that were probed with anti-prM.  
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Figure 10: Western Blot Analysis Comparisons of Construct Infiltrated 
Supernatants Ran on a 20%,70% Sucrose Gradient. (A) Western blot probed 
with a polyclonal antibody targeting the Zika E protein (poly anti-Zika E). 
(B) Western blot probed with a polyclonal antibody targeting the Zika prM 
protein (poly anti-Zika prM). (C) Western blot probed with a polyclonal 
antibody targeting the Zika M protein (poly anti-Zika M). (D) Supernatant of 
UN plant probed with anti-M antibody to determine non-specific binding of 
antibody.  
 
3.7 Transmission Electron Microscopy of Expressed Proteins 
TEM revealed particles present just beneath a 10% optiprep gradient and above a 
60% optiprep gradient after sampling using methods previously described. Micrographs 
revealed a particle that was ~100-120 nm wide (Fig. 11). The size of the plant-produced 
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VLPs is the similar to the expected size of ZIKV particles that bleb from the endoplasmic 
reticulum (Salvo et al., 2018). 
 
Figure 11: Transmission Electron Micrograph of Semi-Purified Plant-
Expressed Particle.  
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4. DISCUSSION 
 The systems utilized in this study have the potential to achieve the requirements 
needed for an expression system to combat against future infection with ZIKV. The 
vector used in this study, BeYDV, has long been shown to produce protein in high yield 
and in a short amount of time (Mor et al., 2003). In addition the agroinfiltration 
techniques used in this study could be translated to the larger scale production of the 
VLP in this study, needed to create a ZIKV vaccine, through processes like vacuum 
infiltration (Matsuo et al., 2016). Presence of proper ZIKV epitopes was also 
demonstrated in this study in addition to overall cost effectiveness of the methodology.   
 The aim of the expression cassette was initially to produce the BASP protein in 
addition to the pr, M, and E proteins of ZIKV. If uncleaved, there would appear a 75 kDa 
band and if cleaved the E protein should appear around 54 kDa, the M protein should 
appear around 8 kDa and the pr protein should appear around 10 kDa (as depicted in 
Figure 5). In theory, these proteins would self-assemble as VLPs by blebbing out of the 
plant ER membrane and these VLPs would contain conformational epitopes like those of 
the native Zika virus. The DNA sequence that encoded the prM was included in an effort 
to produce a conformationally correct Zika E protein, as the Zika prM is believed to aid 
in the correct conformational scaffolding and folding of the E protein during viral 
maturation (Lorenz et al., 2002). The Zika E protein is arguably the most important of 
the proteins contained in the production of the VLP, as it is the target for the largest 
amount of neutralizing antibodies by host infected cells (Dai et al., 2016). For this 
reason, correct folding of the Zika E protein is sought after.  
 Initial findings in this study tested the mere presence of any of the proteins 
encoded by pBYR2eK2M-ZprME expression cassette in the soluble fraction of the 
extraction. The presence of the Zika E protein in the soluble fraction at the expected size 
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of the E protein (~54 kDa) indicates the protein is being secreted in virions by the plant 
infected cells. The sub viral particles assemble in the ER of the cell. It is then transported 
through the TGN, at which point the immature particle is cleaved by furin (in humans) 
and is exocytosed from the cell (Mukhopadhyay et al., 2005). A protein in the leaves of 
tomato plants has been identified as a furin-like protease that cleaves a protein known as 
systemin into smaller polypeptides and likely contributes to the processing of prME in 
plants within this study (Schaller and Ryan, 1996). Prior to this cleavage event of the 
immature particle by furin, the particle undergoes multiple cleavage events in the ER by 
host signal peptidases (Y. Zhang et al., 2003). 
In this study the VLPs likely blebbed from the ER membrane, similar to the 
native virus (Hasan et al., 2018). Such an occurrence would cause the particles to be in 
the soluble fraction. This result is seen in Figure 6A, in both the leaf tissue sample 
extracted in PBS and in the sample extracted in PBS and 1% Triton. Both samples also 
appeared to display bands of the same intensity when the soluble fraction was tested. 
This result also indicates the addition of the Triton X detergent did not cause a major 
difference in the amount of conformationally correct Zika E proteins extracted from the 
sample that could be detected by the monoclonal antibody that targeted the Zika E 
domain II-III fusion loop. It should be considered that this antibody is more likely to 
target proteins that are transitioning from their immature state to their mature state, 
since the Zika E domain II-III fusion loop (residues 98-109) is normally buried by 
domains I and II of the other ZIKV E monomer. The fusion loop is generally only 
displayed between virus entry between a host cell and viral membranes (Dai et al., 2016). 
Though the antibody could likely still target the epitope, it might be possible that more 
Zika E is present in the samples that does not display signal when probed with the 
monoclonal antibody. It is also possible that there is protein containing this epitope that 
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was never cleaved from the M and pr proteins (~75 kDa) but that the other proteins 
hinder the display of the fusion loop and as a result hinder the detection of the E protein, 
even if those proteins are conformationally correct. This result still demonstrates the 
ability for a conformationally correct Zika E protein to be formed through means of plant 
expression and provides hope that the protein may be secreted in virions. 
 The second portion of the experiment displays the acid stability of the formed 
Zika E protein. During the acid precipitation, isoelectric points of proteins and their 
repulsive electromagnetic forces are meant to cancel one another out and equal zero. 
Such an event causes protein aggregation to occur and can result in a much purer final 
product. Past studies have also shown that acid preparation techniques like the one used 
in this experiment are able to remove unwanted plant proteins such as Rubisco from the 
sample (Diamos and Mason, 2018). The samples that were subjected to acid preparation 
(Fig. 6B) displayed approximately the same intensity, when probed with the Zika E 
monoclonal antibody, as the samples that did not undergo acid precipitation when they 
were developed using the same conditions. Such findings indicate that the Zika E protein 
produced by our methods can be purified using acid preparation techniques without loss 
of conformation of the protein or loss of significant yield. 
 The results of the time course allowed for peak expression to be determined. 
Through the use of ImageJ software, as described in the methods, the approximate 
intensity of the bands present on the developed membrane were able to be determined. 
Since the samples from day 3 and 4 DPI were both the highest intensity and almost the 
same under non-reducing conditions when probed with a monoclonal anti-Zika E 
antibody, day 4 was used in the experiments (Fig. 7A, C).  
 Further tests supported the hypothesis that the majority of the conformationally 
correct Zika E protein was present in the soluble fraction. By following the procedure 
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represented by the schematic in Figure 2, the insoluble fraction (pellet of the 
homogenate) was exposed to increasing concentrations of detergent as well as additional 
irritation by metal beads, which in theory would increase protein released from samples. 
The hope was if additional correctly folded Zika E proteins were in the insoluble fraction 
then the increased stress on the leaf tissue would allow them to solubilize which would 
allow optimal amounts of protein to be obtained in future experiments. Though 
increasing amounts of detergent were added to the pellet, there was only signal in the 
supernatant sample when probed with the conformational anti-Zika E monoclonal 
antibody (Fig. 8A). Such results indicate the protein of interest is likely forming a virion 
and allowed us to continue running tests on the soluble fraction rather than on both the 
soluble and insoluble fraction. Since the monoclonal antibody used was seen to only 
efficiently recognize conformationally correct proteins (Fig. 7A), we were only able to run 
the first experiment under non-reducing conditions. The same samples were again run 
under both reducing and non-reducing conditions in an effort to see if more protein 
epitopes would be exposed to the polyclonal antibodies when the proteins were subjected 
to high amounts of SDS and heat. When probed with anti-prM the sample that showed 
the strongest band was just over 50 kDa range in supernatant sample of the pellet that 
was resuspended in PBS+1% triton (Fig. 8B). Since this antibody probe detected both the 
pr and M proteins, the ~50 kDa fragment could be many variations of proteins. Though 
unlikely due to size, it is possible that it is the Zika E with the M protein attached. 
Though there is expected band size for such a protein is much larger than this, as 
indicated in Figure 5.  This result also indicates that the membrane portions of the 
protein might have trouble solubilizing, since so much of it was only detected under 
reducing conditions in the pellet. This would indicate possible different methods of 
protein extraction in the future.  
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 The gel that used the same samples and was probed with a polyclonal anti-Zika E 
showed strong bands in the reduced pellet. This is likely because the antibody was 
produced using a peptide that contained denatured epitopes. As a result, the antibody is 
more likely to see the protein of interest when it is probed against a denatured sample 
(Fig. 8C). This band appeared just above the 50 kDa range, this is close to the expected 
size of the Zika E protein. Finally, the last gel was probed with an anti- Zika M antibody 
and most prominent band was seen in the non-reduced soluble fraction that came from 
the pellet extracted in 1% triton. This could indicate that the M proteins denature when 
exposed to reducing conditions. The bands seen in every row between the 25-37 kDa 
range are likely plant proteins, this will be further explained in Figure 10D.  
 The sucrose gradient tests were initially meant to determine protein density. The 
sucrose gradient setup displayed in (Fig. 3A) was meant to provide sucrose gradients of 
variable density that would allow us to determine approximately which gradient the 
particles no longer are able to travel though. As seen in (Fig. 9), The first few lanes 
contain the supernatant and the 10% fractions. The degradation product of the Zika E 
protein is seen in both of these samples at ~ 38 kDa (Yang et al., 2018). It is thought that 
this formation of the protein is not fully formed and as a result might not elicit the same 
degree of protective immunity against ZIKV infection. 
 In a sucrose gradient, particles travel until they reach the point where their 
density matches the density of the surrounding sucrose (Noll and Noll, 1989). The rate at 
which they travel can be different for each VLP. As seen in Figure 9, the bottom half of 
the 20% fraction has the highest intensity band around ~54 kDa and the top layer of the 
30% fractions continues to display the same band. The bottom layer of the 30% fraction 
and the top layer of the 40% fraction display progressively less intense bands at ~54 kDa. 
This could be due to error in fraction separation when removing the sucrose samples 
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from the initial sucrose gradient tube or could also be aggregated material of the same 
~54 kDa proteins that are present in the 20% fraction that began to separate when they 
reached a denser fraction. It is important to note that the ~38 kDa fragment that is 
present in the soluble fraction and the 10% fraction completely disappears in the deeper 
fractions, indicating that it does not encompass the density of a VLP and is likely not a 
fully formed version of the protein of interest. In each row there also appears to be a 
band at the very top of the gel at ~150 kDa. This band is likely aggregation of the Zika 
proteins that formed. It is also twice the size of the expression of the prME proteins in 
unison (~75kDa). Further tests were performed to determine if other protein 
components were also present in the sample and if VLPs were formed. 
 The presence of the Zika pr and M proteins in the samples could affect the 
efficacy of the resulting VLP upon immunization trials (Lorenz et al., 2002). Primarily, 
sucrose gradients were run following the schematic in Figure 3B, to concentrate 
whatever VLPs were present in the sample. The prior experiment determined the VLPs 
generally pass through the 20% sucrose fraction and into the 30% sucrose fraction, but 
largely are not present in the 40% fraction. It would be likely all Zika virus-like particles 
in future experiments within this study would pass through a 20% sucrose fraction but 
would not be able to pass through a 70% sucrose fraction and would form an “interface” 
band, that would contain the majority of proteins present in that sample. Having a 
concentrated sample would allow for easier detection of proteins when analyzed by 
western blot as they would be more likely to appear upon probing with an antibody. 
Samples were observed under both reducing and non-reducing conditions. When 
samples were observed under non-reducing conditions, only very light signal was seen in 
the 54 kDa range when probed with a polyclonal anti-Zika E, absolutely no signal was 
seen in the regions of interest when probed with the polyclonal anti- Zika prM antibodies 
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and the polyclonal anti-Zika M antibodies. It is likely that all epitopes which the 
antibodies were raised to react against were hidden when the proteins were ran under 
non-reducing conditions and these epitopes could eventually display and be detected for 
signal by HRP linked antibodies when ran under reducing conditions. 
When probed with a polyclonal anti-Zika E antibody, under reducing conditions, 
bands were visualized at ~75 kDa and ~54 kDa, the expected sizes of the full Zika BASP, 
pr, M and E proteins seen in (Fig. 4) A and expected size of the full Zika E protein, 
respectively (Fig 4 E). When probed with the polyclonal anti-Zika E, there was no signal 
detected below or around the 15 kDa range. When probed with polyclonal anti-Zika prM 
antibodies, there was a signal detected again in the ~75 kDa range and below the 20 kDa 
range in the “interface” sample. For this sample there was no signal detected in the 54 
kDa range. Such results indicate the previously viewed ~75 kDa fragment contained both 
the Zika E protein and wither the Zika pr, the Zika M or both. There was no 54 kDa 
fragment in this sample further supporting that the 54 kDa band seen in the previous 
sample was the Zika E protein (Fig. 10A, B). The band below the 20 kDa range could 
have been either the Zika pr (~10kDa), the Zika M protein (~8 kDa) or aggregation of 
both. It is important to note that there were also bands present in the 0%, 20% sucrose 
samples as well as the interface sample that were below 15 kDa. These bands were not 
present in the 70% sucrose or in the wildtype. They were also not present in the gels that 
were probed with anti-Zika E or anti-Zika M. These bands could have been cleaved pr. 
There was additionally a band seen below the 25 kDa but above the 20 kDa range in the 
20% fraction of material (Fig. 10B). It is thought that this signal could also be indicative 
of pr, which should occur in the situation of mature VLP formation, that likely 
aggregated and would not be dense enough to travel to the “interface” (Lorenz et al., 
2002; Y. Zhang et al., 2003).  
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To determine whether the segment below 20 kDa was the pr or the M, the same 
“interface” sample was probed with polyclonal anti- Zika M antibodies. It was 
determined that the ~75 kDa fragment was still present and that the fragment below the 
20 kDa range also continued to display signal (Fig. 10C). Such results indicate the 
presence of the Zika M protein in the ~75 kDa fragment and that the band just below 20 
kDa that appeared in gels probed with both anti-Zika prM and anti-Zika M was likely the 
Zika M protein. It is likely then that the segments found beneath the 15 kDa range were 
the Zika pr protein since they did not appear when probed with anti-Zika M. Based on 
the size and the signal of the proteins present, it was determined that expression of the 
Zika pr, M, and E proteins were achieved. 
In addition, ZIKV has 6 sites of glycosylation in its envelope and 4 sites of 
glycosylation in its membrane (Gupta et al., 2016). Such a circumstance could cause the 
estimated 63kDa protein (Fig. 4) to appear larger on a gel, indicating that that the ~75 
kDa fragment viewed on the developments could be the fully formed, glycosylated Zika 
ME protein with pr cleaved off. 
We were never able to run samples that were probed with the Zika E monoclonal 
antibody as reducing samples because the monoclonal was conformational and would 
not recognize any of the proteins in their denatured states. The experiment displayed in 
Figure 10 was also run under non-reducing conditions (results not show). In these tests, 
he proteins were not able to be visualized at the 75 kDa range. This likely is because 
epitopes were hidden and even if they were present, were not able to be visualized by 
western blot as a result. Considering this find, it is possible there were ~75 kDa 
fragments or ~63 kDa fragments in those samples but that they were never able to be 
visualized due to the nature in which the antibodies recognized epitopes.  
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The next step in the process of determining VLP formation was visualization of 
the proteins and determination of the size. To do this a semi-purified preparation of the 
material was to be made. To increase the yield of protein and VLP formation, PEG was 
added to the isolated supernatant.  PEG precipitation has been shown to aid in the 
accumulation of protein and when used above a concentration of 6% has been shown to 
aid in the formation of VLPs that mimic other viruses (Diamos and Mason, 2018b). 
OptiPep, unlike sucrose, can be viewed under a TEM microscope without the need for 
dialysis (Van Veldhoven et al., 1996). Optiprep was used for this reason to isolate the 
VLP and visualize the components of certain fractions. The Optiprep gradient was set up 
as is shown in Figure 3C. OptiPrep gradients are also twice as dense as sucrose gradients. 
For this reason, it was predicted that the VLPs would travel through the 10% OptiPrep 
gradient and would remain above the 40% gradient. When the sucrose gradients were 
performed, plant proteins were seen in the 70% sucrose as well as the bottom of the tube. 
For this reason, it was determined the plant proteins could be isolated as well, as they 
would pass into but not past the 40% Optiprep gradient and be separated from the VLPs. 
TEM was thus performed on the “interface” band present between the 10% and 40% 
fraction of the OptiPrep gradient after centrifugation.  
When TEM was performed on the interface band tested under TEM was taken 
from the gradient that contained the 2 hr PEG precipitation since the overnight PEG 
precipitation was much greener in color and oversaturation of proteins viewed under the 
TEM was trying to be avoided. The TEM taken from the OptiPrep gradient particles that 
resembled those of Zika virus were visualized at about 100 nm-120 nm (Fig. 11). This size 
correlates with the expected size of formed VLPs that assemble in the ER, as viral 
particles can be a range of sizes depending on their method of formation (Santi et al., 
2006).  
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This research demonstrates the ability for plants to produce native ZIKV 
proteins. These findings could aid in the creation of a ZIKV vaccine candidate of low cost, 
high scalability and efficient immunogenicity. The low cost of plant production can have 
a huge impact on the ability to distribute and administer vaccines. Plants are able to 
produce extensive amounts of biomass and resultant protein using far less capital than 
requirements to produce the same product in cell-culture facilities (Chen and Davis, 
2016). This study also demonstrates that the utilization of a geminiviral vector is able to 
produce recombinant protein that at a rate faster than other vectors utilized in plant 
biotechnology past studies (Yang et al., 2018).  
 The BeYDV system containing the Zika prME expression cassette (Fig. 5), was 
able to produce protein very quickly through agroinfiltration in this study, as shown in 
Figure 7. It is imperative to note that protein was produced in a conformationally correct 
way as early as 2 DPI (Fig. 7A, C) using this system. Such circumstances indicate that the 
system could be used to produce protein even quicker than 4 days if circumstances 
require the therapeutic immediately. In addition, the BeYDV used in this study was able 
to produce peak protein expression of Zika E in only 4 days, as compared to previous 
studies that utilized ICON expression systems and were able to produce Zika E protein at 
peak levels at 6 DPI (Yang et al., 2018). Degradation products below 54 kDa were 
detected in this study as well as previous studies that aimed to produce the Zika E 
protein (Yang et al., 2018).  Elimination of this segment can be performed through 
density gradients that separate the proteins and dialysis or other purification methods to 
isolate only the correct 54 kDa fragment.   
 Expressing the Zika E and M proteins contain complications. One such 
complication is the fact that both the E and M protein require proteolytic processing. As 
shown in Figure 1, processing of these proteins requires both signal peptidases and Golgi 
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proteases. Both proteases originate in the host system ER and TGN. Not all prM-E 
heterodimers are cleaved by furin though and uncleaved heterodimers will revert back to 
immature trimeric structures (Dai et al., 2016). Since enzymes in plants are different, the 
proteins produced in plants might not be cleaved as easily as when they are produced in 
humans. Though studies on plants have determined the presence of furin-like proteases 
(Schaller and Ryan, 1996) in some plants, it is not yet known if plants contain the same 
ER signal peptidases that are needed for proper cleavage of the Zika polyprotein (Fig. 1). 
Other studies have successfully produced flavivirus membrane proteins in various 
expression systems other than plants such as DENV membrane proteins in mammalian 
cells (Bray and LAl, 1991), Japanese Encephalitis virus (JEV) membrane proteins 
through DNA vaccines (Konishi et al., 1998) and production of JEV membrane proteins 
in HeLa cells and in modified mammalian cell lines (Konishi et al., 2001, 1992). Each of 
these trials successfully produced flavivirus membrane proteins and most were able to 
test for and elicit an immune response upon viral challenge (Bray and LAl, 1991; Konishi 
et al., 1998, 1992).  
 Signal peptidases are enzymes that cleave the signal peptides from the end 
terminals of some secretory and membrane proteins in an effort to produce the mature 
forms of these proteins. They are ER-derived serine proteases that originally isolated in 
mouse myeloma cells (MILSTEIN et al., 1972). Orthologs of both signal peptidases and 
signal peptidase-like proteins have been identified in vertebrates, plants and eukaryotes 
as highly conserved sequences within each (Voss et al., 2013). These peptidases as 
needed to cleave and process prME (Fig. 1) and their high conservation makes it likely 
that such events will occur when proteins containing signal peptidase cleavage sites are 
produced in plants (Ponting et al., 2002; Voss et al., 2013).  
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Correct processing of the Zika prME also requires cleavage by a Golgi protease 
known as furin (in humans). The proposal that pr is cleaved in this study is supported by 
the existence of furin analogs in plants (Schaller and Ryan, 1996). A furin-like protease 
has been identified in the leaves of tomato plants and potato plants. This enzyme cleaves 
a protein known as systemin into smaller polypeptides and likely contributes to the 
processing of prME in plants within this study (Schaller and Ryan, 1996). The protein 
was termed SBP-50 and it was thought to have held similarity to members of kez2p-like 
proteases. These kez2p- like proteases allow for maturation of peptide hormones 
(Schaller and Ryan, 1996). The presence of both these signal peptidases and furin-like 
proteases support the ability for plants to correctly process the Zika prME and supports 
the cogency of the results found in this study. 
 For a particle to be considered a VLP, it must contain dense, repetitive arrays of 
one or more protein subunits that have high advantage of use in eliciting an immune 
response (Chackerian, 2007). The dense repetitive arrays allow for crosslinking of a BCR 
after an antigen is presented to it, such a circumstance allows for B cell activation and 
eventual formation of a long lived adaptive immune response (Bachmann and 
Zinkernagel, 1997; Zabel et al., 2013). In order for this dense repetitive array to exist 
within the viral particle, not every portion of the native structural viral polyprotein must 
be present. Though Zika Virus is comprised of three structural proteins the (C, E, M 
proteins) (Davidson, 2009; Hasan et al., 2018), not all proteins are required to create the 
repetitive arrays needed in a VLP to elicit an adaptive immune response within a host. 
For this reason, it is not believed that the ZIKV C protein is needed in VLP formation or 
that its inclusion would produce drastically different results in terms of elicitation of an 
immune response. The C protein of ZIKV aids in packaging the viral genome and 
formation of the nucleocapsid core (Hasan et al., 2018), while the E protein elicits the 
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largest amount of neutralizing antibodies when present in a host and the pr (initially 
presented as the prM) allows for proper folding of the Zika E protein (Dai et al., 2016; 
Hasan et al., 2018). The C protein is not necessary for immune responses as it does not 
carry a large role in eliciting immunogenicity and therefore does not need to be included 
in the VLP.  
 Past studies that have excluded the C protein in DENV VLPs found similar 
efficacies, in terms of immune response, as those elicited by the inactivated virus (Liu et 
al., 2010). When studies included the C protein (also for DENV) they were able to find 
correct particle formation (Fu et al., 1997) though the study did not state weather or not 
the VLPs elicited immunity in a host that was comparable to an inactivated virus. In 
addition, trials in which VLPs were produced from the prME of JEV showed 
immunogenicity and protection in mice that were given lethal challenge of JEV (Konishi 
et al., 1992). These results indicate that inclusion of the C protein in flavivirus VLPs is 
not necessary to generate a proper host immune response. 
In the current study we present the ability to quickly produce ZIKV VLPs that 
contain the native ZIKV pr, M, and E proteins in N. benthamia plants. In addition, we 
show that these proteins are like the authentic Zika virus in both conformation and 
approximate size. VLPs in the past have been regarded as promising vaccine candidates 
due to their ability to self-assemble structures that resemble native viruses. As a result, 
VLPs are able to present authentic epitopes to the immune system and elicit high titer 
antibody responses by B-cells through creation of memory B cells or long-lived plasma 
cells (Chackerian, 2007; Murphy and Weaver, 2016; Zabel et al., 2013). 
 In recent years, Zika Virus has infected millions of people, has been 
demonstrated to be a teratogen (including being the causal agent of neurodevelopmental 
pathologies such as microcephaly afflicting of thousands of babies), and has been 
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correlated with GBS in adults (Adibi et al., 2016; Cao-Lormeau et al., 2016; Faria et al., 
2016; Petersen et al., 2016; Ritter et al., 2017). While the epidemics in South and Central 
America subsided globally there remain areas with compatible insect vectors and human 
populations that are naïve to the Brazilian strain of ZIKV (most of Asia, large parts of 
Africa, southern Europe and the southern US) where ZIKV outbreaks may take pandemic 
proportions. Moreover, climate change may expand the spread of the mosquito vectors 
to more northerly areas in the US, Canada and Europe. It is therefore very likely that we 
have not yet heard the last of ZIKV. The world has been given an amnesty to better 
prepare for the next wave of ZIKV outbreaks by developing efficacious, cost-effective, 
safe and globally available prophylactic and therapeutic interventions. The results of this 
study provide the initial steps to a means that would allow for cost-effective prophylactic 
intervention of ZIKV.  
5. FUTURE WORK  
 If signal is detected in the pellet after incubation with the polyclonal antibodies 
used in this study then it would be beneficial to add a denaturing reagent to the pellet, 
such as urea or guanidine in an effort to unfold the protein from its native conformation 
and to bring the protein into solution (Pace, 1986). After this is complete, the protein 
could be refolded, as to reform the protein structure. This protein could then be ran 
through a sucrose gradient to determine if there is presence of the proteins of interest in 
this study, how dense they are and what size they might be. Such an experiment would 
allow for optimum protein yield to be achieved. 
 Determination of the immune response initiated by these VLPs in mice would 
also be helpful in determining the immunogenicity of the plant produced VLP. Immune 
cell response assays could be completed as a result of this experiment to determine what 
the vaccine might do inside of a human host. These immunological assays could include 
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cytokine assays performed on splenocyte samples post immunization with the VLP. The 
most cytokines to measure would likely be IFN-gamma, IL-4 and IL-6, as these cytokines 
are the most likely to be excreted in response to the actual ZIKV (Ball, 1994; Hamel et 
al., 2015).   
 The described study sheds light on methods that can be used to develop and 
isolate Zika VLPs. These developments pave the way for further research in the realm of 
plant-produced pharmaceuticals and development of therapeutics that can be available 
to people living in areas with little income and limited access to healthcare. 
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